|
Old Dog, New Tricks: Oxybutynin for the Treatment of Androgen Deprivation Therapy–Related
Vasomotor Symptoms
Mar 26, 2026 Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer Mar 26, 2026 Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/DPYD) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing Mar 26, 2026 Dear Doctor: We Still Have No Idea of What Dose of Capecitabine You Should Prescribe Mar 26, 2026 Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer Mar 26, 2026 Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer Mar 26, 2026 Old Dog, New Tricks: Oxybutynin for the Treatment of Androgen Deprivation Therapy–Related Vasomotor Symptoms Mar 26, 2026 Fullerene for Reducing Acute Radiation Dermatitis in Patients Undergoing Radiotherapy for Head and Neck Cancer: A Phase II, Double-Blind, Randomized Controlled Trial Mar 26, 2026 Results From the Genetic Information and Family Testing Study: A Cluster-Randomized Trial Mar 26, 2026 Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial Mar 26, 2026 Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study Mar 26, 2026 Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 Mar 26, 2026 Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery Mar 26, 2026 Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery Mar 26, 2026 Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery Mar 26, 2026 Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery Mar 26, 2026 From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer Mar 26, 2026 Reply to: From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer Mar 26, 2026 Reply to: From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer Mar 26, 2026 From Thresholds to Tumor Sidedness: Reframing Human Epidermal Growth Factor Receptor 2 in Colorectal Cancer Mar 26, 2026 |
Bridging the Gap: What We Can Learn From LEAP-010 in Recurrent/Metastatic Head and Neck Cancer Journal of Clinical Oncology, Volume 44, Issue 12, Page 1068-1071, April 2026. <br/> 2026-04-20T07:00:00Z Financial Hardship Before Diagnosis: Influence on Late-Stage Cancer Presentation and the Role of Screening Journal of Clinical Oncology, Volume 44, Issue 12, Page 1130-1138, April 2026. <br/> 2026-04-20T07:00:00Z Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial Journal of Clinical Oncology, Volume 44, Issue 12, Page 1120-1129, April 2026. <br/> 2026-04-20T07:00:00Z CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer Journal of Clinical Oncology, Volume 44, Issue 12, Page 1076-1082, April 2026. <br/> 2026-04-20T07:00:00Z Good Oncologist: Doctoring Lessons From the Art of Oncology Journal of Clinical Oncology, Volume 44, Issue 12, Page 1166-1173, April 2026. <br/> 2026-04-20T07:00:00Z VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer Journal of Clinical Oncology, Volume 44, Issue 12, Page 1108-1119, April 2026. <br/> 2026-04-20T07:00:00Z Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update Journal of Clinical Oncology, Volume 44, Issue 12, Page 1145-1165, April 2026. <br/> 2026-04-20T07:00:00Z Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study Journal of Clinical Oncology, Volume 44, Issue 12, Page 1098-1107, April 2026. <br/> 2026-04-20T07:00:00Z Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII) Journal of Clinical Oncology, Volume 44, Issue 12, Page 1083-1097, April 2026. <br/> 2026-04-20T07:00:00Z Target Trial Emulation for Regulatory and Clinical Decision Making in Cancer Journal of Clinical Oncology, Volume 44, Issue 12, Page 1139-1144, April 2026. <br/> 2026-04-20T07:00:00Z When the System Is the Treatment: Rethinking Nonpharmacologic Breakthroughs in Oncology Journal of Clinical Oncology, Volume 44, Issue 12, Page 1072-1075, April 2026. <br/> 2026-04-20T07:00:00Z Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases Journal of Clinical Oncology, Volume 44, Issue 12, Page 1174-1174, April 2026. <br/> 2026-04-20T07:00:00Z Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials Journal of Clinical Oncology, Volume 44, Issue 12, Page 1174-1175, April 2026. <br/> 2026-04-20T07:00:00Z Expanding Indications for Stereotactic Radiosurgery in Small Cell Lung Cancer With Brain Metastases Journal of Clinical Oncology, Volume 44, Issue 12, Page 1175-1177, April 2026. <br/> 2026-04-20T07:00:00Z Reply to: “Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases,” “Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials,” and “Expanding Indications for Stereotactic Radiosurgery in Small Cell Lung Cancer With Brain Metastases” Journal of Clinical Oncology, Volume 44, Issue 12, Page 1177-1178, April 2026. <br/> 2026-04-20T07:00:00Z How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability Journal of Clinical Oncology, Volume 44, Issue 12, Page 1065-1067, April 2026. <br/> 2026-04-20T07:00:00Z |
Membranoproliferative Glomerulonephritis Due to Cryoglobulinemia
A 60-year-old woman with follicular lymphoma was evaluated for swelling and proteinuria that had persisted for 2 weeks. The patient’s plasma was clear at 37°C but turbid at 4°C. A kidney biopsy was performed. 2026-04-25
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer Among men with locally advanced prostate cancer, transdermal estradiol was noninferior to LHRH agonists for 3-year metastasis-free survival and led to a lower incidence of hot flashes but a higher incidence of gynecomastia. 2026-04-23
Asundexian for Secondary Stroke Prevention In a placebo-controlled trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. 2026-04-16
Ianalumab plus Eltrombopag in Immune Thrombocytopenia In a phase 3 trial, ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag, with a stable platelet response at 6 months in a higher percentage of patients with 9 mg/kg of ianalumab than with placebo. 2026-04-16
Sex Hormone Influences on Venous Thrombotic and Cardiovascular Risk Combined oral contraceptives and hormone-replacement therapy increase the risk of venous thromboembolism, although the absolute risk is low. Transdermal estradiol and micronized progesterone carry lower risk. 2026-04-16
Asundexian for Noncardioembolic Ischemic Stroke Despite the implementation of efficacious interventions for secondary prevention, patients with ischemic stroke or transient ischemic attack (TIA) remain at substantial residual risk for short- and long-term recurrent ischemic stroke and coronary events.1,2 Approximately three quarters of ischemic strokes or TIAs are noncardioembolic and may be attributable to... 2026-04-16
The Dismantling of Environmental Protections — A Grave Threat to America’s Health The Trump administration’s wide-ranging actions to dismantle U.S. environmental regulations will cause long-lasting health harms, disproportionately affecting low-income and other vulnerable groups. 2026-04-16
Hepatic Pseudoprogression after Treatment with Nectin-4–Targeted Antibody–Drug Conjugate In a patient with metastatic cervical cancer treated with the nectin-4–targeted antibody–drug conjugate bulumtatug fuvedotin, a new hepatic lesion proved to be pseudoprogression and resolved with continued therapy. 2026-04-16
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer In a phase 1 trial of first-line zongertinib for HER2-mutated non–small-cell lung cancer, an objective response occurred in 76% of patients, with a median progression-free survival of 14.4 months. 2026-04-15
EGFR’s Poor Sibling The discovery that many lung cancers are driven by a single dominant constitutively activated “driver” oncogene represented a quantum leap in the therapy of lung cancer. Potent small molecules were developed that could turn off these genes, with dramatic clinical therapeutic efficacy. Before their discovery, cancer therapeutics were identified by... 2026-04-15
Stenting for Post-Thrombotic Syndrome — A Step Forward Post-thrombotic syndrome is the most common chronic complication of deep-vein thrombosis (DVT), affecting 20 to 50% of patients with DVT and causing debilitating symptoms involving the limbs — including pain, swelling, skin changes, and venous ulcers — that substantially reduce quality of life and impose considerable socioeconomic burden.1 ... 2026-04-13
A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia Among adults with persistent or chronic ITP, the incidence of adverse events with mezagitamab appeared to be similar to that with placebo. Mezagitamab treatment appeared to result in increased platelet counts at all three doses tested. 2026-04-09
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer In a phase 1 trial of setidegrasib, a KRAS G12D degrader, 42% of patients had adverse events of grade 3 or higher; 36% of patients with NSCLC and 24% of those with pancreatic cancer had a response. 2026-04-09
Altering the Diet to Rewire Cancer A study in a mouse model of MYCN-amplified neuroblastoma implicates polyamine levels in affecting the makeup of the proteome and biologic characteristics of the tumor. 2026-04-09
Necrolytic Migratory Erythema An 83-year-old woman with worsening type 2 diabetes presented with a 6-month history of painful rash. Hyperpigmented plaques with coalescing erosions and blisters were seen. Abdominal CT revealed a mass in the tail of the pancreas. 2026-04-09
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease In this study, a Cas12a–guide RNA complex was used to target the promoters of HBG1 and HBG2 in autologous stem cells to treat sickle cell disease. 2026-04-02
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. 2026-04-02
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia In this study, a Cas12a–guide RNA complex was used to target the promoters of HBG1 and HBG2 in autologous stem cells to treat transfusion-dependent β-thalassemia. 2026-04-02
More Options for Gene Editing in Hemoglobinopathies Transfusion-dependent β-thalassemia and sickle cell disease, both characterized by defective hemoglobin synthesis, are the most common monogenic diseases worldwide. Each year, approximately 60,000 infants are born with transfusion-dependent β-thalassemia, and 500,000 infants receive a diagnosis of sickle cell disease.1,2 Historically, patients with these disorders have rarely survived beyond... 2026-04-02
Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy Although bladder preservation with trimodal therapy is a category 1 recommendation in the National Comprehensive Cancer Network (NCCN) guidelines for appropriately selected patients with muscle-invasive bladder cancer, the real-world adoption of this type of therapy in the United States remains disappointingly low. Contemporary data suggest that only half the patients... 2026-04-02
|
|
|
| |||
|
[Editorial] War in the Middle East: collateral damage
A month after the USA and Israel launched attacks on Iran, Iran and the USA agreed to a conditional 2-week ceasefire on April 8, 2026. However, strikes continued in Lebanon, and after peace talks failed to come to a resolution an end to the war is no closer at the time of writing and the situation in the region remains precarious. Furthermore, the effects of the US–Israel–Iran war are being felt not only in the region, but also globally, and the impact on health care worldwide is under-appreciated and likely long-lasting. Fri, 01 May 2026 00:00:00 -0700
[Comment] AKT-targeted triplet therapy in advanced breast cancer The advent of CDK4/6 inhibitors combined with endocrine therapy has substantially transformed the treatment approach for patients with HR+/HER2– metastatic breast cancer;1 however, acquired resistance inevitably develops, making the optimal sequencing of subsequent targeted therapies a substantial challenge. Aberrant activation of the PI3K/AKT/PTEN signalling axis is frequently identified as a key contributor to CDK4/6 inhibitor cross-resistance, providing a robust biological rationale for therapeutic intervention. Fri, 01 May 2026 00:00:00 -0700
[Comment] Beyond efficacy: CDK4/6 inhibitors in metastatic breast cancer Over the past decade, phase 3 trials have consistently demonstrated substantial progression-free survival and overall survival improvements with the addition of CDK4/6 inhibitors to endocrine therapy. The meta-analysis of Beshr and colleagues1 in The Lancet Oncology provides the most up-to-date analysis of data from phase 3 trials comparing CDK4/6 inhibitors plus endocrine therapy with endocrine therapy alone. By consolidating survival results, efficacy of this drug class in treatment of HR+/HER2– metastatic breast cancer is reaffirmed. Fri, 01 May 2026 00:00:00 -0700
[Comment] An old tool for new strategies in advanced prostate cancer Prostate-specific antigen (PSA) was discovered in 1960 and introduced as a biomarker for prostate cancer in 1987.1 Since then, PSA has been used for screening, detecting recurrence after prostatectomy or radiotherapy, and monitoring treatment response. Early work also demonstrated that PSA concentrations measured 6–9 months after initiating castration represent a major prognostic factor in metastatic castration-sensitive prostate cancer.2 Fri, 01 May 2026 00:00:00 -0700
[Comment] Refined outcome prediction in patients with extremity soft tissue sarcoma The rarity and heterogenous presentation of extremity soft tissue sarcomas complicates large-scale studies on diagnosis, disease monitoring, and outcome prediction. Histological subtype, grading, tumour size, location, resectability (with wide margins), administration of adjuvant or neoadjuvant radiotherapy, and chemotherapy all influence oncological outcomes, including local recurrence and risk of distant metastasis, as well as overall survival (figure).1 Given that the estimated prognosis of patients with soft tissue sarcoma guides decisions on individual treatment concepts, patient counselling, and follow-up strategies,2 the accurate prediction of oncological outcomes is important. Fri, 01 May 2026 00:00:00 -0700
[Comment] Ionising radiation and cancer: a UN review of the recent epidemiological evidence In 2019, the UN Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), whose mandate is to undertake scientific evaluations of the sources, effects, and risk of ionising radiation,1–3 convened a group of experts to review the latest epidemiological evidence on radiation and cancer risk. The updated report focuses on low-level radiation exposures; it has recently been approved and will be published in 2026.4 Fri, 01 May 2026 00:00:00 -0700
[Comment] Academic clinical cancer trials to improve patient outcomes Cancer clinical trials are conducted by both the commercial and non-commercial sectors. Whereas clinical trials conducted by the commercial sector aim for the marketing authorisation of new drugs, the primary characteristic of independent clinical trials conducted by the academic sector is the capacity to address a wide range of clinical research questions that are generally not addressed by the drug development industry. Crucial examples include the optimisation of surgical and radiation treatments, drug dose and treatment duration, multimodality combinations, sequence of treatments, head-to-head comparison of therapeutic strategies, better identification of patients who will or will not benefit, and addressing the needs of underserved patient populations. Fri, 01 May 2026 00:00:00 -0700
[Correspondence] CAR T-cell therapy at first relapse in myeloma We congratulate Hermann Einsele and colleagues on their phase 3 CARTITUDE-4 trial, a landmark study poised to reshape the therapeutic landscape of relapsed myeloma. By finding a significant overall survival advantage with ciltacabtagene autoleucel (cilta-cel) compared with pomalidomide–bortezomib–dexamethasone or daratumumab–pomalidomide–dexamethasone in patients with lenalidomide-refractory myeloma with one to three previous lines of therapy, CARTITUDE-4 provides compelling evidence that earlier use of CAR T-cell therapy can alter disease trajectory. Fri, 01 May 2026 00:00:00 -0700
[Correspondence] CAR T-cell therapy at first relapse in myeloma – Authors' reply We thank Jowon Laura Kim and S Vincent Rajkumar for their comments. Fri, 01 May 2026 00:00:00 -0700
[Correspondence] How flaws in study design and lead-time bias could affect the interpretation of data We read with interest the systematic review by C Tang and colleagues1 and compliment the authors for their comprehensive primary analysis of six randomised clinical trials (RCTs) comparing metastasis-directed therapy (MDT) with standard of care (SOC) in oligometastatic prostate cancer. However, we identified several important design concerns and methodological limitations that could compromise the validity and interpretation of the findings. Fri, 01 May 2026 00:00:00 -0700
[Correspondence] How flaws in study design and lead-time bias could affect the interpretation of data – Authors' reply We thank André Vis and Kim de Vries for their interest in our WOLVERINE study.1 We agree that, optimally, there will be well conducted phase III trials to inform the benefit of metastasis-directed therapy (MDT) for oligometastatic prostate cancer. However, these trials have yet to be reported, and in the interim, clinicians are left with an increasingly common clinical scenario that requires evidence-based direction. The highest-level data available are randomised phase 2 trials. However, heterogeneity exists between these trials given inherent differences and the timeframes over which they were run. Fri, 01 May 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: e218–30 Alger E, Regnault, A, Dueck AC, et al. A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR). Lancet Oncol 2026; 27: e218–30—The appendix of this Policy View has been corrected as of April 27, 2026. Fri, 01 May 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 461–69 Privé BM, Noordzij W, Muselaers CHJ, et al. [177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study. Lancet Oncol 2026; 27: 461–69—In this Article, the title has been corrected to “[177Lu]Lu-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study”. This correction has been made to the online version as of April 27, 2026. Fri, 01 May 2026 00:00:00 -0700
[News] Carcinogenicity of tris(chloropropyl) phosphate, butyraldehyde, and cumyl hydroperoxide In March, 2026, a Working Group of 12 scientists from nine countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to finalise their evaluation of the carcinogenicity of tris(chloropropyl) phosphate (TCPP), butyraldehyde, and cumyl hydroperoxide. Fri, 27 Mar 2026 08:00:04 +0000
[News] US oil blockade pushes Cuba's health system into crisis A US oil blockade causing several power blackouts in Cuba has led to tens of thousands of delayed surgeries while the health system tries to prioritise urgent care, including radiotherapy for 16 000 patients with cancer and chemotherapy for another 12 400 patients with cancer, say Cuban health authorities and the UN. Fri, 27 Mar 2026 23:30:01 +0000
[News] US cancer vaccines research at “tipping point” as NCI backs $200 million initiative The US National Cancer Institute (NCI) and the Foundation for the National Institutes of Health have launched a partnership to raise nearly US$200 million to fund clinical trials for cancer vaccines, including mRNA-based approaches for patients at high risk of tumour recurrence. Fri, 27 Mar 2026 23:30:01 +0000
[News] Senators demand explanation for US Preventive Services Task Force halt 19 US senators wrote to Health and Human Services Secretary Robert F Kennedy Jr on March 24, 2026, demanding he explain why the US Preventive Services Task Force (USPSTF)—the independent expert panel that has determined which cancer screenings and other preventive care Americans can access at no cost for four decades—has not met for a year. They called on Kennedy to submit an overdue, legally required annual USPSTF report to Congress, and to fill five vacancies among the 16 Task Force seats. Thu, 02 Apr 2026 22:30:01 +0000
[News] Canada's Yukon Territory publishes First Nations Cancer Strategy Canada's vast Yukon Territory in the country's northwest has published its first ever First Nations Cancer Strategy, aiming to improve cancer diagnosis, treatment, and care across the board for its First Nations people, who make up just less than 20% of the territory's population of around 48 000 people (2025 estimate). Some three-quarters of the population live in Whitehorse, the territory's capital near the southern border with the Province of British Colombia. Thu, 02 Apr 2026 22:30:03 +0000
[News] European Breast Cancer Conference 2026 Preliminary results of the ADARNAT pilot phase suggest that axillary radiotherapy (ART) without lymphadenectomy might safely replace axillary lymphadenectomy (ALND) in patients with limited node disease. Amparo Garcia-Tejedor (Hospital Universitari de Bellvitge, Gynecology, Hospitalet de Llobregat, Spain) presented results from the pilot phase of ADARNAT trial, an open-label, randomised, phase 3 multicentre trial across 23 Spanish hospitals. 272 patients with breast cancer (cT1–T4b, and cN0–cN1) treated with neoadjuvant therapy and 1–2 positive sentinel lymph nodes at surgery were randomly assigned to receive ART or ALND. Thu, 02 Apr 2026 22:30:01 +0000
[News] UK MHRA–NICE pathway to create faster regulatory approval A new aligned pathway has been established by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) to facilitate earlier patient access to medicines, according to recently published guidance. Fri, 10 Apr 2026 22:30:01 +0000
[News] Trump's 2027 budget calls for further cuts to health research Medical groups are preparing to lobby Congress over health cuts proposed in the 2027 budget by the US Trump administration in the hope that lawmakers will ensure funding when spending plans are negotiated in the coming months. Thu, 16 Apr 2026 22:30:01 +0000
[Perspectives] CHEMO MAN—or how we used to remember It caught my attention one Sunday as I did inpatient rounds. Pinned to a corkboard, fading slightly at the edges, the drawing looked almost childish at first glance. A smiling stick figure labelled CHEMO MAN, organs sketched in block letters and arrows pointing outwards with names of drugs and toxicities carefully written in pen. Doxorubicin for the heart. Bleomycin for the lungs. Cisplatin for the kidneys. Methotrexate for the liver. Vincristine for the nerves. A mnemonic rendered as a body and, unintentionally, a theory of learning. Fri, 01 May 2026 00:00:00 -0700
[Perspectives] Turning breast cancer into art with Cancer Research UK On Jan 20–25, 2026, the Business Design Centre in London, UK, hosted the annual London Art Fair, which for the first time had Cancer Research UK (London, UK) as its official charity partner. Cancer Research UK, used their platform at the London Art Fair to showcase two artists whose lives have been affected by breast cancer. Tucked away in a quiet upstairs corner of the fair, slightly aside from the bustling central area, Cancer Research UK's relatively small exhibition displayed the works of Dr Helen Anahita Wilson and Carole Ellis, two revolutionary and incredibly talented artists and survivors of breast cancer. Fri, 01 May 2026 00:00:00 -0700
[Articles] Estimating total and diagnosed global cancer incidence and stage distribution from 1990 to 2050: a simulation-based analysis of 17 cancers These findings highlight the substantial and growing burden of cancers, especially in low-income and middle-income countries, where many people who develop cancer die undiagnosed. Accounting for demographic and epidemiological trends as well as health system factors, our modelling framework enables evaluation of targeted interventions to strengthen the cancer workforce and improve diagnostic pathways across diverse geographical and socioeconomic settings. Fri, 01 May 2026 00:00:00 -0700
[Articles] Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancers Disparities in global cancer survival are large and are expected to persist on current trends without transformative policy action. Our modelling framework provides comprehensive, country-level projections of survival and mortality for multiple cancers, accounting for demographic and epidemiological trends, as well as health system barriers and workforce constraints. Fri, 01 May 2026 00:00:00 -0700
[Articles] Estimating the impact of scaling up workforce personnel on global cancer mortality from 2030 to 2050: a simulation-based analysis of 17 cancers and 18 personnel types Investments to strengthen the cancer workforce will be essential to reduce global cancer mortality and improve timely diagnosis and survival. Strategic scale-up of personnel, particularly in diagnostics, alongside innovative strategies such as digital health solutions and role delegation, could result in substantial improvements in cancer outcomes. Policy makers should prioritise data-driven workforce planning as a crucial component of comprehensive cancer control strategies. Fri, 01 May 2026 00:00:00 -0700
[Articles] Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2– metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial The combination of fulvestrant, ipatasertib, and palbociclib showed preliminary signs of clinical activity and showed expected adverse events in heavily pretreated patients with HR+/HER2– metastatic breast cancer, warranting further evaluation in those with CDK4/6 inhibitor-refractory disease. Fri, 01 May 2026 00:00:00 -0700
[Articles] CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials CDK4/6 inhibitors plus endocrine therapy significantly improved survival in hormone receptor-positive, HER2-negative advanced breast cancer. Benefits in progression-free survival and overall survival were consistent across major clinical subgroups. Although all agents improved progression-free survival, only ribociclib and abemaciclib showed statistically significant overall survival benefits, whereas palbociclib did not, and data for dalpiciclib remain immature. Further head-to-head comparisons and assessments of toxicity profiles, as well as patient-reported outcomes, are needed. Fri, 01 May 2026 00:00:00 -0700
[Articles] Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials Performing SLNB or cALND solely to determine eligibility for CDK4/6 inhibition requires very high number needed to diagnose and treat, adds substantial morbidity, and is costly, with only marginal overall survival benefit. Fri, 01 May 2026 00:00:00 -0700
[Articles] Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial Along with the known survival benefits, the clinically meaningful delays in pain progression and time to deterioration of overall wellbeing support consideration of darolutamide plus ADT as a standard-of-care treatment option in patients with mHSPC. Thu, 09 Apr 2026 22:30:01 +0000
[Articles] On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials Metastatic volume or nodal status influence survival rates associated with on-treatment serum PSA categories, including for undetectable PSA. Radiological features and serum PSA could be combined to better predict survival. PSA at 24 weeks showed strongest associations with overall survival, although a PSA concentration of 0·2 ng/mL or less at any timepoint predicted favourable outcome. These findings could inform prognosis and warrant evaluation for treatment selection in clinical trials. Fri, 01 May 2026 00:00:00 -0700
[Articles] Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study BayeSarc is a continuously updatable, accurate, and precise prognostic tool for soft tissue sarcomas in the extremities. It reduces uncertainty, adapts to temporal changes, and refines variable weights. Its incorporation into the Sarculator app enables immediate clinical use, with potential to improve patient counselling, guide treatment decisions, and refine trial design. More broadly, the BSL framework provides an innovative and generalisable approach to prognostication in rare cancers, moving beyond the traditional two-step development–validation paradigm, enabling more efficient use of patient data. Fri, 01 May 2026 00:00:00 -0700
[Policy Review] Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium Oligometastatic cancer is characterised by a low volume of metastases to a small number of anatomical sites. However, evaluating the impact of metastases-directed therapies (MDTs) on overall survival or quality of life is often challenging. Current clinical trials use a wide range of primary endpoints that might not be validated or suited to MDT. To address this issue, we did a systematic review of international trial registries, alongside a Delphi consensus process involving 30 experts and five patient representatives. Fri, 01 May 2026 00:00:00 -0700
[Policy Review] International multisociety Delphi consensus for liver tumour thermal ablation: margin assessment This multisociety, multidisciplinary consensus—formally endorsed by the European Society of Surgical Oncology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Oncology—was developed to standardise the assessment of ablation margins in liver tumour thermal ablation. A modified Delphi process, consisting of two online surveys and a hybrid (online and in-person meeting in Innsbruk) consensus meeting of 72 experts from North America, South America, Europe, and Asia. Fri, 01 May 2026 00:00:00 -0700
[Policy Review] International multisociety Delphi consensus for liver tumour thermal ablation: procedural and practice standards Thermal ablation offers a safer, less invasive, and more cost-effective curative-intent treatment for selected patients with primary and metastatic liver tumours than surgery; when done with appropriate technique, ablation can deliver similar oncological outcomes. However, effectiveness in routine practice varies because structured training, planning, and procedural governance remain scarce. These international multidisciplinary, multi-society guidelines—formally endorsed by the European Society of Surgical Oncology, the Cardiovascular and Interventional Radiological Society of Europe, and the Society of Interventional Oncology—define key domains contributing to procedural difficulty and practice variation in liver tumour thermal ablation. Fri, 01 May 2026 00:00:00 -0700
|
Drug development trajectory of anticancer drugs after initial pediatric‐eligible trials
Oncology drugs entering testing in children and adolescents are at high risk of attrition, including low rates of subsequent late phase trials and pediatric regulatory approvals. Mon, 27 Apr 2026 21:50:47 -0700 Eligibility criteria for cancer drug trials in adult patients: Evidence from China, 2013–2021 These findings highlight a need for more inclusive and modernized eligibility criteria for the advancement of cancer clinical trials in China. Mon, 27 Apr 2026 21:24:45 -0700 Multigene germline testing for epithelial ovarian cancer in China Over 25% of Chinese EOC patients carry germline HR‐related gene variants, which are associated with better treatment response and survival. Broad genetic testing is critical, and the prognostic value of VUS warrants further investigation. Sun, 26 Apr 2026 22:02:39 -0700 Neoadjuvant chemotherapy for soft‐tissue sarcoma of the extremities: A post‐hoc Sarculator‐based risk analysis of the EORTC 62961–ESHO 95 randomized trial This analysis of ESTS from a randomized trial confirmed the previously reported OS benefit by adding RHT to NAC. Although patients with higher predicted risk seemed to benefit more from the combined treatment, these findings do not suggest that treatment decisions should be based on risk estimates alone, supporting the use of RHT combined with chemotherapy in patients who have primary ESTS. Sun, 26 Apr 2026 11:24:51 -0700 Cost‐effectiveness of interventions to increase colorectal cancer screening among populations with low screening uptake Multicomponent interventions to increase the use of FIT kits represent an effective and efficient strategy for increasing CRC screening uptake in FQHCs. Sat, 25 Apr 2026 07:39:08 -0700 Acute myeloid leukemia after myeloproliferative neoplasms: Real‐world outcomes in the new treatment era in the United States This study highlights allo‐HCT as the only potentially curative option with both IC and LIT serving as effective bridging therapies. Sat, 25 Apr 2026 06:59:30 -0700 Fianlimab, a human lymphocyte activation gene‐3 monoclonal antibody, in combination with cemiplimab: Tumor‐specific expansion cohorts in advanced malignancies Fianlimab plus cemiplimab demonstrated modest clinical efficacy with an acceptable safety profile in patients with advanced malignancies across several tumor types mostly in treatment‐naive patients. Further investigation is warranted. Fri, 24 Apr 2026 04:56:29 -0700 Poverty in the residential and surrounding counties and its impact on mortality in women with breast cancer Thu, 23 Apr 2026 22:21:40 -0700 Disability‐adjusted life‐years from human papillomavirus‐related oral cavity and pharynx cancers in US men, 2017–2021 Tonsillar cancers carried the highest DALY burden among HPV‐associated OPCs in US men. Patients who were aged 65 years and older and were never vaccine‐eligible presented significant DALY increases across all cancer subsites, emphasizing the need for gender‐neutral HPV vaccination and catch‐up programs for high‐risk older men. Wed, 22 Apr 2026 11:24:48 -0700 Issue Information Wed, 22 Apr 2026 11:08:32 -0700 |
Survival of Patients Diagnosed With Cancer During the COVID-19 Pandemic
This cohort study investigates the association of the COVID-19 pandemic with short-term survival among patients diagnosed with cancer in 2020 and 2021 using US population-based cancer registry data. Salvage Focal Therapy vs Radical Prostatectomy for Localized Radiorecurrent Prostate Cancer This cohort study compares cancer control and perioperative complications among patients after salvage focal therapy vs salvage radical prostatectomy. Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial This secondary analysis examines 15-year follow-up data from a randomized clinical trial to evaluate the potential for long-term remission and cure for follicular lymphoma following chemoimmunotherapy with cyclophosphamide, hydroxydaunorubicin/doxorubicin, oncovin, and prednisone/prednisolone (CHOP)–based regimens. Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer This cohort study evaluated the performance and generalizability of 2 open-source artifical intelligence models in predicting mutations in Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations This cohort study evaluates the association between adjuvant imatinib and recurrence-free survival and overall survival in patients with resected high-risk gastrointestinal stromal tumors (GISTs) with BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin Lymphoma This secondary analysis of the GHSG HD21 randomized clinical trial evaluates the tolerability and impact of BrECADD vs escalated BEACOPP on health-related quality of life for patients with Hodgkin lymphoma. Cardiovascular Events in Women With Prior Cervical High-Grade Squamous Intraepithelial Lesion This cohort study examines cardiovascular disease risk, incidence, and mortality among adolescents and young adults with cervical high-grade squamous intraepithelial lesions (HSILs). Pericardial Effusion and Bruton Tyrosine Kinase Inhibitors in B-Cell Malignant Disease This cohort study examines the association of bruton tyrosine kinase inhibitor therapy in B-cell malignant disease with increased risk of pericardial effusion and cardiovascular outcomes. New Retroperitoneal Soft-Tissue Lesion in Multiple Myeloma A 67-year-old man with a history of λ light-chain multiple myeloma presents with increased serum-free λ light chain levels. What is your diagnosis? Making Veterans Visible in National Cancer Registries This Viewpoint discusses improving US cancer surveillance systems to address veteran-specific risks and outcomes. The Time for Cancer Vaccines Is Now: Advancing Toward Lasting Cancer Immunity This Viewpoint discusses advances in cancer vaccines, including the use of COVID-19 pandemic–related infrastructure, clinical trial results, and harnessing artificial intelligence. Cancer Research and Public Health Literacy—Making Sense This Viewpoint examines the challenges and strategies for improving public health literacy related to cancer research and care, including effective communication and ethical engagement among researchers, health care professionals, and patients. Risk-Based Screening for Breast Cancer: Time to Focus on Implementation Lessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer—The Sooner, the Better? Redefining Salvage Therapy for Localized Radiorecurrent Prostate Cancer—In More Ways Than One Taking Care of Your Mouth During Cancer Treatment This Between Ambition and Duty—A Path That I Did Not Choose This essay describes a turn of events that compelled a medical oncology fellow to learn to care for young patients with sarcoma and to rediscover why he chose medicine in the first place. Meeting the Mirror Prostate-Specific Membrane Antigen PET-Guided Salvage Radiotherapy—Precision or Prematurity? Prostate-Specific Membrane Antigen PET-Guided Salvage Radiotherapy—Precision or Prematurity?—Reply Risk Factors for Valvulopathy Among Childhood Cancer Survivors Risk Factors for Valvulopathy Among Childhood Cancer Survivors—Reply Competing Risk of Death in Heart Failure or Cardiomyopathy Prediction After Breast Cancer Competing Risk of Death in Heart Failure or Cardiomyopathy Prediction After Breast Cancer—Reply Physical Activity, Lifestyle, and Cancer Risk Physical Activity, Lifestyle, and Cancer Risk—Reply Cribriform-Positive and -Negative Prostate Cancer Cribriform-Positive and -Negative Prostate Cancer—Reply JAMA Oncology |
|
|
| |||
|
[Editorial] From diagnosis to equitable care in bleeding disorders
Up to three-quarters of people with haemophilia worldwide are estimated to be undiagnosed, with an even bigger gap predicted for other bleeding disorders. This astonishing statistic underlies the focus of this year's World Haemophilia Day, on April 17, on diagnosis: a first step to care. Even when people are diagnosed, there are substantial inequalities in access to treatment and bleeding prophylaxis in many parts of the world. 2026 could mark a crucial year for turning the tide on these issues, with the recent approval of a World Health Assembly (WHA) resolution on Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders, which will be presented at the 79th WHA on May 18–23, 2026, for final adoption. Wed, 01 Apr 2026 00:00:00 -0700
[Comment] Updated anaemia estimates: implications for global monitoring In 2024, WHO updated haemoglobin thresholds and revised the adjustments for altitude and smoking.1 The earlier elevation adjustments were established in 1989 and were based on a demographically limited subset of populations and did not adequately represent the diversity of global populations. The 2024 updated elevation adjustment was based on the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project, which leverages multinational surveys with broader geographical and demographic representation than previous methods. Wed, 01 Apr 2026 00:00:00 -0700
[Comment] Maintenance intensification after autologous HSCT: refining selection In The Lancet Haematology, Dominik Dytfeld and colleagues1 report the findings from the phase 3 ATLAS trial, comparing carfilzomib–lenalidomide–dexamethasone with lenalidomide alone as maintenance therapy after autologous haematopoietic stem-cell transplantation (HSCT) in patients with newly diagnosed multiple myeloma. Lenalidomide monotherapy has long been the global standard of care in this setting, based on consistent improvements in progression-free survival and overall survival.2 With a median follow-up of nearly 6 years, carfilzomib–lenalidomide–dexamethasone maintenance significantly improved 4-year progression-free survival (67·5% [95% CI 56·2–76·4] vs 38·0% [27·6–48·2]; hazard ratio 0·46 [95% CI 0·30–0·70]) with a manageable safety profile. Wed, 11 Mar 2026 23:30:01 +0000
[Correspondence] Patient selection and treatment sequencing in RESMAIN The RESMAIN trial by Rudolf Stadler and colleagues, published in The Lancet Haematology, showed that resminostat maintenance therapy significantly prolonged median progression-free survival (median 8·3 months, 95% CI 4·2–15·7) compared with placebo (4·2 months, 2·8–6·4) in patients with advanced-stage mycosis fungoides or Sézary syndrome.1 These diseases are characterised by repeated cycles of remission and relapse. Therefore, progression-free survival does not carry the same clinical implications as in acute leukaemia or solid tumours, in which relapse is often associated with worse survival. Wed, 01 Apr 2026 00:00:00 -0700
[Correspondence] Patient selection and treatment sequencing in RESMAIN – Author's reply I would like to thank Takashi Miyachi and colleagues for their Correspondence regarding the RESMAIN trial. The most prevalent forms of cutaneous T-cell lymphoma are mycosis fungoides and its variants, as well as Sézary syndrome. According to the current guidelines, in the early stages of the disease, the recommended therapeutic approach is based on skin-directed therapies. In more advanced stages of the disease, the recommended treatment involves primarily non-toxic systemic drugs, such as pegylated interferon, bexarotene, and combinations with radiotherapy or extracorporeal photopheresis. Wed, 01 Apr 2026 00:00:00 -0700
[Corrections] Correction to Lancet Haematol 2026; 13: e169–80 Olíva EN, Cottone F, Unni S, et al. Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial. Lancet Haematol 2026; 13: e169–80—In figure 2 of this Article, the two groups were incorrectly labelled “Q+stdCT” and “Q+stdCT” instead of “Q+stdCT” and “P+stdCT”. This correction has been made as of April 2, 2026. Wed, 01 Apr 2026 00:00:00 -0700
[Corrections] Correction to Lancet Haematol 2026; published online March 11. https://doi.org/10.1016/S2352-3026(26)00064-5 Perrot A, Frenzel L. Maintenance intensification after autologous HSCT: refining selection. Lancet Haematol 2026; published online March 11. https://doi.org/10.1016/S2352-3026(26)00064-5—In this Comment, the title should have been Maintenance intensification after autologous HSCT: refining selection. This correction has been made as of March 19, 2026. Thu, 19 Mar 2026 23:30:01 +0000
[Corrections] Correction to Lancet Haematol 2026; 13: e241–53 Dytfeld D, Wróbel T, Jamroziak K, et al. Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial. Lancet Haematol 2026; 13: e241–53—Anna Puła's affiliations should have been “Medical University of Lodz, Lodz, Poland” and “University of Chicago, Chicago, IL, USA”. Agnieszka Druzd-Sitek's and Prof Jan Walewski's affiliation should have been “Maria Skłodowska-Curie National Research Institute of Oncology, ERN EuroBloodNet, Warsaw”. Wed, 01 Apr 2026 00:00:00 -0700
[News] WHO resolution pushes for global equity in haemophilia care WHO has adopted a resolution to advance health equity for people with haemophilia and other bleeding disorders. Led by Armenia and co-sponsored by 12 countries across Europe, Asia, Africa, and the Americas, the resolution was approved by the WHO Executive Board (EB158) meeting on Feb 3, 2026, and aims to improve access to care and treatment worldwide. Armen Melkonyan, Head of International Relations at the Ministry of Health in Armenia, presented the resolution, which seeks to establish an international framework to improve care and treatment for people with haemophilia and other bleeding disorders. Wed, 01 Apr 2026 00:00:00 -0700
[In Focus] Concomitant or sequential lower intensity triplet therapy in AML Jayastu Senapati and Naval G Daver Wed, 01 Apr 2026 00:00:00 -0700
[In Focus] Scientific progress in the shadow of regional instability I write on a day of unexpected personal and professional convergence. This past week, I spent long days in strategic discussions on enabling cell and gene therapy programmes—expanding access to advanced therapeutics and building infrastructure so that patients in our region might benefit from innovation at home rather than waiting for it to become available elsewhere. The work was forward-looking and ambitious. Yet I awoke today to news and sounds of interception explosions that, for the first time, felt unexpectedly and uncomfortably close to my new home, the United Arab Emirates. Wed, 01 Apr 2026 00:00:00 -0700
[Articles] Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial Deucrictibant significantly reduced the severity of hereditary angioedema attacks compared with placebo; these results support continued investigation of antagonism of the bradykinin B2 receptor with an orally available agent as a potentially effective approach, with a safety profile similar to placebo, for on-demand treatment. Thu, 19 Mar 2026 23:30:03 +0000
[Articles] Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial To the best of our knowledge, this trial provides the first clinical evidence and proof-of-concept for bradykinin B2 receptor antagonism as a therapeutic approach for the prevention of hereditary angioedema attacks and supports further investigation of oral deucrictibant for bradykinin-mediated angioedema. Thu, 19 Mar 2026 23:30:01 +0000
[Articles] Implications of changes in WHO haemoglobin elevation adjustment guidelines on global, regional, and national anaemia burden, 1990–2023: a population-based modelling study Understanding the effect of anaemia requires unbiased and comparable estimates of anaemia burden. To our knowledge, we produced the first set of global estimates of anaemia burden by location, year, age, and sex using the WHO 2024 elevation adjustment method and compared them with estimates using the previous method. Policy makers should consider this modification when designing interventions to manage and prevent anaemia, particularly in regions most affected by changes in elevation adjustment. Wed, 01 Apr 2026 00:00:00 -0700
[Articles] Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial The enhanced efficacy of carfilzomib–lenalidomide–dexamethasone treatment following autologous HSCT in patients with newly diagnosed multiple myeloma, assessed within a framework of de-escalation based on MRD status and individual risk, supports strategies for maintenance therapy intensification in this setting. Wed, 11 Mar 2026 23:30:02 +0000
[Viewpoint] Building safeguards for gene therapy in haemophilia Haemophilia care has progressed through successive therapeutic revolutions, from plasma-derived and recombinant factor replacement to extended half-life products and non-factor therapies. The introduction of gene therapy, with currently approved approaches using adeno-associated viral vectors to deliver functional copies of the factor VIII or IX gene into hepatocytes, now represents the next paradigm shift: a one-time, irreversible intervention designed to restore endogenous factor production. Although early results are promising, the experience of transfusion transmitted infections reminds the haemophilia community that innovation must be matched by vigilance, transparency, and accountability. Tue, 10 Mar 2026 22:30:01 +0000
[Viewpoint] Balancing the benefits and risks of rebalancing coagulation in haemophilia Rebalancing agents represent a novel therapeutic class in haemophilia, designed to restore the deficient thrombin generation that underlies bleeding. Unlike factor replacement or factor VIII mimetic therapies, rebalancing agents act by downregulating natural anticoagulants. By partially inhibiting these physiological brakes of coagulation, they induce a controlled and reversible procoagulant shift. These agents have shown clinically meaningful reductions in bleeding rates across both haemophilia A and B, including in patients with inhibitors. Tue, 10 Mar 2026 23:30:01 +0000
|
Donor T cells on double duty: VCAR33 for AML after transplant
Volume 147, Issue 17 April 23 2026 Engineering ABO histocompatibility in transplant and beyond Volume 147, Issue 17 April 23 2026 Beyond the code: noncoding splicing rewires mutant SF3B1 Volume 147, Issue 17 April 23 2026 Common variants, rare disease: new insights into AML risk Volume 147, Issue 17 April 23 2026 lncRNA and protein team up to drive immune cell identity Volume 147, Issue 17 April 23 2026 Fueling, then wrecking the megakaryocyte ship Volume 147, Issue 17 April 23 2026 Novel phosphatase-based regulatory loop for HbF expression Volume 147, Issue 17 April 23 2026 What next after the first BITE of the CD19 cherry in ALL? Volume 147, Issue 17 April 23 2026 How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide With the increasing adoption of posttransplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis, survival outcomes after HLA-mismatched donor hematopoietic cell transplantation are now comparable to those achieved with HLA-matched donors. Shaffer, Lee, and Perales review how this paradigm shift influences donor selection decisions and provide illustrative case vignettes highlighting concepts applicable to different clinical scenarios.
Volume 147, Issue 17 April 23 2026 A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT VCAR33 is a donor-derived anti-CD33 chimeric antigen receptor-modified (CAR) T-cell developed for relapsed acute myeloid leukemia (AML) following allogeneic hematopoietic cell transplantation. Mushtaq et al report a phase 1/2 study of 15 adults with relapsed or measurable residual disease–positive AML or myelodysplastic syndrome with a generally manageable toxicity profile of mostly low-grade cytokine release syndrome, limited neurotoxicity, and one case of grade III graft-versus-host disease. There is a 20% response rate and evidence of in vivo expansion, supporting early anti-leukemic activity.
Volume 147, Issue 17 April 23 2026 Selective depletion of ABO-responsive B cells by T-cell–engaging bispecific antibody conjugates for ABOi transplantation There is a critical need for targeted approaches to eliminate ABO-responsive B cells to enable ABO-incompatible solid organ transplantation. While anti-CD20 therapies such as rituximab are effective, they cause broad B-cell depletion and increase infection risk. Choi et al describe a T-cell–recruiting bispecific antibody–ligand conjugate that selectively eliminates blood group–responsive B cells, demonstrating depletion of A antigen–specific B cells in human peripheral blood mononuclear cells with efficacy comparable to rituximab while sparing bystander B cells, supporting further development toward human translation.
Volume 147, Issue 17 April 23 2026 Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability Oncogenic mutations in SF3B1 are among the most common lesions in myeloid malignancies and chronic lymphocytic leukemia, classically linked to aberrant splicing of protein-coding sequences. Sekrecki et al uncovered a previously unrecognized function, showing that mutant SF3B1 rewires noncoding mRNA splicing to drive malignant phenotypes while creating therapeutic vulnerabilities. Specifically, missplicing of DCAF16 increases its protein expression, suggesting the potential to exploit BRD4-targeting protein degraders in SF3B1-mutant disease. This work reframes SF3B1 biology by demonstrating that altered splicing of untranslated regions can promote gain-of-function effects and reveal new treatment strategies.
Volume 147, Issue 17 April 23 2026 Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy comprising multiple biologically distinct subgroups. Ranasinghe et al identified a new genome-wide significant risk locus for pan-AML, along with 3 additional loci associated with specific subgroups, including AML with chromosome 5 and/or 7 deletions and cytogenetically complex disease. They also show that variants linked to clonal hematopoiesis risk are similarly associated with AML. These findings refine our understanding of AML etiology and highlight shared genetic susceptibility with clonal hematopoiesis.
Volume 147, Issue 17 April 23 2026 The C/EBPα-(PU.1-LOUP) regulatory circuit regulates monocyte/macrophage development and immune functions Volume 147, Issue 17 April 23 2026 Single-cell profiling of ANKRD26 thrombocytopenia reveals progenitor expansion and polyploid apoptosis via JUNB-p21 ANKRD26-related thrombocytopenia 2 (THC2) is a rare inherited platelet disorder caused by germline variants in the 5′ untranslated region of ANKRD26. Chen et al investigated defective megakaryopoiesis in THC2 by using single-cell transcriptomics and ex vivo functional profiling of bone marrow samples from 4 affected patients. They identified reproducible abnormalities in progenitor expansion and increased apoptosis of polyploid megakaryocytes, and they propose a novel mechanism in which centrosomal overexpression of ANKRD26 drives polyploid megakaryocyte apoptosis through JUNB-mediated induction of p21 transcription.
Volume 147, Issue 17 April 23 2026 An optimized CRISPR-Cas12a genome-wide screen reveals PTPA phosphatase pathway in fetal hemoglobin silencing Volume 147, Issue 17 April 23 2026 Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL With increasing frontline use of blinatumomab for acute lymphoblastic leukemia (ALL), its impact on subsequent CD19 chimeric antigen receptor (CAR) T-cell therapy outcomes is a key clinical question. Srinagesh et al leveraged data collected by the Real-World Outcomes Collaborative of CAR-T in Adult ALL consortium for 271 adults, and they report that prior nonresponse to blinatumomab was associated with inferior survival after brexucabtagene in comparison to blinatumomab-naïve patients (12-month progression-free survival, 33% vs 60%; overall survival, 51% vs 72%). Notably, early CAR-T responses were uniformly high (∼90% complete remissions with or without hematologic recovery at day 28) regardless of prior exposure or response. These data highlight that resistance to blinatumomab may identify patients at higher risk of post–CAR T relapse despite excellent initial responses.
Volume 147, Issue 17 April 23 2026 B-lymphoblastic leukemia with synchronous KMT2A::TXNRD1 and IGH::CEBPD rearrangements Volume 147, Issue 17 April 23 2026 NPM1-mutated acute myeloid leukemia with a hybrid granulocytic and monocytic phenotype Volume 147, Issue 17 April 23 2026 Carter BZ, Mak PY, Ayoub E, et al. Restoring p53 wild-type conformation in TP53-Y220C–mutant acute myeloid leukemia. Blood. 2025;146(21):2574-2588. Volume 147, Issue 17 April 23 2026 Volume 147, Issue 17 April 23 2026 |
Hydroxyurea Delays the Onset of Hyposplenism in Young Children With Sickle Cell Disease
Mon, 27 Apr 2026 18:54:33 -0700 Outcomes With First‐Line PD1 Inhibitors in Extranodal NK/T‐Cell Lymphoma: A Comparative Analysis From a 755‐Patient Multicenter Cohort Sun, 26 Apr 2026 18:54:55 -0700 Multicenter Real‐World Analysis of Glofitamab in Relapsed/Refractory Primary CNS Lymphoma: Clinical Activity, CNS Penetration, and ctDNA Dynamics Sat, 25 Apr 2026 22:35:33 -0700 Hyper‐CVAD Versus Hyper‐CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome‐Negative Acute Lymphoblastic Leukemia: A Propensity‐Score Analysis Sat, 25 Apr 2026 21:49:20 -0700 Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia Sat, 25 Apr 2026 21:15:17 -0700 Blinatumomab and Ponatinib Versus Hyper‐CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis Fri, 24 Apr 2026 18:55:39 -0700 Mind the Gap: Underdosing of Intravenous Iron in a Hospitalized Patient Population With Iron‐Deficiency Anemia Fri, 24 Apr 2026 05:25:21 -0700 Real‐World Outcomes of FLAG‐Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study Wed, 22 Apr 2026 00:00:00 -0700 A Novel Plasma Heme Assay Reveals Disease Severity in Beta‐Thalassemia and Sickle Cell Anemia Wed, 22 Apr 2026 00:00:00 -0700 The Emerging Role of Liver Stiffness Measurement in Transfusion Dependent Thalassemia Tue, 21 Apr 2026 21:11:18 -0700 Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference Tue, 21 Apr 2026 20:45:10 -0700 Long‐Term Quality of Life in 1777 Persons With Hodgkin Lymphoma and 6166 Matched Comparators Sat, 18 Apr 2026 08:05:45 -0700 Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities Fri, 17 Apr 2026 23:36:01 -0700 High‐Altitude Hypoxemia in Adults With Sickle Cell Disease (SCD) Fri, 17 Apr 2026 23:29:53 -0700 Mixed Type Autoimmune Hemolytic Anemia: Clinical Severity and Treatment Patterns in a Large Observational Study Fri, 17 Apr 2026 21:10:36 -0700 Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics Fri, 17 Apr 2026 21:00:45 -0700 Real‐World Outcomes of Mycosis Fungoides and Site‐Specific Nodal Involvement: A Registry‐Based Study of 25 467 Patients Thu, 16 Apr 2026 04:29:15 -0700 Dabigatran Concentrations in an Actively Breastfeeding Mother–Infant Dyad: Extending the Evidence for Oral Thromboprophylaxis Postpartum Thu, 16 Apr 2026 00:00:00 -0700 Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience Thu, 16 Apr 2026 00:00:00 -0700 The Role of Allogeneic Hematopoietic Cell Transplantation in the Management of Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors Wed, 15 Apr 2026 23:20:44 -0700 Accelerated Clonal Hematopoiesis and Premature Hematopoietic Aging in Benzene‐Exposed Populations Tue, 14 Apr 2026 18:45:06 -0700 |
|
|
| |||
|
Exercise in MPNs: a promising first step April 14 2026 - Volume 10, Issue 7 FAST: a 5-minute assay for measuring fibrinolytic activation April 14 2026 - Volume 10, Issue 7 Earlier CAR-T: fewer cytopenias, bigger questions April 14 2026 - Volume 10, Issue 7 Neutrophil CD14: expanding the deep vein thrombosis framework April 14 2026 - Volume 10, Issue 7 In response to stress: quicker, yet bigger April 14 2026 - Volume 10, Issue 7 Refining prognostic tools in Waldenström macroglobulinemia April 14 2026 - Volume 10, Issue 7 A different alternative to warfarin? April 14 2026 - Volume 10, Issue 7 Zamtocabtagene autoleucel: dual CD20-CD19 targeting for NHL April 14 2026 - Volume 10, Issue 7 Mechanism(s) of factor XI inhibition in clinical practice April 14 2026 - Volume 10, Issue 7 Monovalent antibody treatment of von Willebrand disease April 14 2026 - Volume 10, Issue 7 Pumping up immunity: exercise flexes memory NK cell attack April 14 2026 - Volume 10, Issue 7 How to determine the optimal duration of anticoagulation for VTE: an evidence-based decision-analytical approach April 14 2026 - Volume 10, Issue 7 Biology of von Willebrand disease April 14 2026 - Volume 10, Issue 7 Treatment and survival outcomes for patients with follicular lymphoma and POD24: a systematic review and meta-analysis April 14 2026 - Volume 10, Issue 7 Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation April 14 2026 - Volume 10, Issue 7 Bone marrow transplantation for sickle cell disease using posttransplantation cyclophosphamide and 400 cGy TBI April 14 2026 - Volume 10, Issue 7 Zamtocabtagene autoleucel in relapsed/refractory B-NHL: 5-year follow-up of a CD20/19 tandem CAR T-cell phase 1 trial April 14 2026 - Volume 10, Issue 7 Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study April 14 2026 - Volume 10, Issue 7 Improved survival and health care use with CAR-T vs historical care in relapsed/refractory large B-cell lymphoma April 14 2026 - Volume 10, Issue 7 Osteocyte-derived erythroferrone regulates liver hepcidin during stress erythropoiesis April 14 2026 - Volume 10, Issue 7 The bone marrow niche and hematopoietic system are distinctly remodeled by CD45-targeted astatine-211 radioimmunotherapy April 14 2026 - Volume 10, Issue 7 Exercise-mobilized lymphocytes enhance the function of cytokine-induced memory-like NK cells against myeloid leukemia April 14 2026 - Volume 10, Issue 7 Serum free fatty acid promotes tumor progression and predicts golidocitinib sensitivity in peripheral T-cell lymphoma April 14 2026 - Volume 10, Issue 7 POD24 is a novel determinant of prognosis in patients with Waldenström macroglobulinemia April 14 2026 - Volume 10, Issue 7 MPN-FIT: a randomized controlled pilot trial of supervised exercise in myeloproliferative neoplasms April 14 2026 - Volume 10, Issue 7 Advancing precision therapy in pediatric acute myeloid leukemia through PDX models and mitochondrial targeting April 14 2026 - Volume 10, Issue 7 Prospective feasibility study of peripheral blood for MRD detection in acute myeloid leukemia by flow cytometry April 14 2026 - Volume 10, Issue 7 Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML April 14 2026 - Volume 10, Issue 7 The alarmin interleukin-33 modulates platelet proteome, function, and biogenesis April 14 2026 - Volume 10, Issue 7 Epo and hypoxia accelerate a pattern of gradual cell cycle shortening in BFU-e and CFU-e erythroid progenitors in vivo April 14 2026 - Volume 10, Issue 7 Lipid metabolism transcriptomic signature of defective erythropoiesis in Diamond Blackfan anemia syndrome April 14 2026 - Volume 10, Issue 7 Atrial fibrillation prevalence and its management in aging, transfusion-dependent patients with thalassemia: the FATHAL study April 14 2026 - Volume 10, Issue 7 Rapid detection of fibrinolytic activation in postpartum hemorrhage and acute obstetric coagulopathy using a novel assay April 14 2026 - Volume 10, Issue 7 Neutrophil CD14 is a driver and a therapeutic target for deep vein thrombosis April 14 2026 - Volume 10, Issue 7 Targeting PAR1 biased signaling with parmodulin reduces thromboinflammation and acute lung injury in sickle cell disease April 14 2026 - Volume 10, Issue 7 Small-molecule inhibition of γ-glutamyl carboxylase reveals a novel anticoagulant strategy April 14 2026 - Volume 10, Issue 7 RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran) April 14 2026 - Volume 10, Issue 7 HMB-002: a monovalent antibody that elevates circulating VWF and FVIII levels for treatment of von Willebrand disease April 14 2026 - Volume 10, Issue 7 HCT Pre-App program: a telemedicine-based prehabilitation for allogeneic hematopoietic cell transplant candidates April 14 2026 - Volume 10, Issue 7 Differential effects of GVHD therapies on intestinal epithelium April 14 2026 - Volume 10, Issue 7 Clonal dynamics, tolerance, and adverse events after CD45-ADC–conditioned autologous HSPC transplantation in macaques April 14 2026 - Volume 10, Issue 7 Allogeneic hematopoietic stem cell transplantation in ERCC6L2 disease April 14 2026 - Volume 10, Issue 7 Platelet α-granule cargo packaging and endocytosis are important for normal mouse skin wound healing April 14 2026 - Volume 10, Issue 7 Ropeginterferon alfa-2b has minimal transplacental passage and breastmilk secretion in pregnant patients with MPN April 14 2026 - Volume 10, Issue 7 Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden April 14 2026 - Volume 10, Issue 7 Significant burden of low-grade infections in patients treated with T-cell−engaging therapies for multiple myeloma April 14 2026 - Volume 10, Issue 7 Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial April 14 2026 - Volume 10, Issue 7 SARS-CoV-2 spike protein can bind fibrin(ogen), but does not alter plasma fibrin formation, clot structure, or lysis April 14 2026 - Volume 10, Issue 7 Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report April 14 2026 - Volume 10, Issue 7 Blinatumomab limits humoral antibody response despite boosting the influenza vaccine schedule in children with B-ALL April 14 2026 - Volume 10, Issue 7 Thrombosis in primary myelofibrosis: the influence of cohort composition and disease biology April 14 2026 - Volume 10, Issue 7 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer
New England Journal of Medicine, Volume 394, Issue 16, Page 1595-1607, April 23, 2026.
Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults New England Journal of Medicine, Volume 394, Issue 16, Page 1608-1620, April 23, 2026.
Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients New England Journal of Medicine, Volume 394, Issue 16, Page 1583-1594, April 23, 2026.
Spinal Epidural Abscess New England Journal of Medicine, Volume 394, Issue 16, Page 1621-1633, April 23, 2026.
Evolocumab for Primary Prevention of Cardiovascular Disease New England Journal of Medicine, Volume 394, Issue 16, Page 1656-1659, April 23, 2026.
Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction New England Journal of Medicine, Volume 394, Issue 16, Page 1659-1661, April 23, 2026.
Blood-Pressure Control after Intracerebral Hemorrhage — An Unbroken Glass Ceiling New England Journal of Medicine, Volume 394, Issue 16, Page 1647-1648, April 23, 2026.
Bronchial Casts from Inhalation of Forest-Fire Smoke New England Journal of Medicine, Volume 394, Issue 16, Page 1634-1634, April 23, 2026.
Case 12-2026: An 86-Year-Old Woman with Anorexia, Weight Loss, and Liver Lesions New England Journal of Medicine, Volume 394, Issue 16, Page 1635-1645, April 23, 2026.
Goals of Care and the Importance of Being Polish New England Journal of Medicine, Volume 394, Issue 16, Page 1568-1569, April 23, 2026.
Closing the Evidence Gap for Drugs in Children — Measures to Strengthen the Pediatric Research Equity Act New England Journal of Medicine, Volume 394, Issue 16, Page 1566-1568, April 23, 2026.
Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis New England Journal of Medicine, Ahead of Print.
High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure New England Journal of Medicine, Ahead of Print.
IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease New England Journal of Medicine, Ahead of Print.
Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism New England Journal of Medicine, Ahead of Print.
Iptacopan in IgA Nephropathy — Final 24-Month Data New England Journal of Medicine, Ahead of Print.
Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy New England Journal of Medicine, Ahead of Print.
A Phase 3 Trial of Brepocitinib in Dermatomyositis New England Journal of Medicine, Ahead of Print.
Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial New England Journal of Medicine, Ahead of Print.
Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock New England Journal of Medicine, Ahead of Print.
A Multicomponent Intervention to Improve Maternal Infection Outcomes New England Journal of Medicine, Ahead of Print.
Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation New England Journal of Medicine, Ahead of Print.
Sirolimus-Eluting Technology for the Treatment of Peripheral Artery Disease New England Journal of Medicine, Ahead of Print.
Left Atrial Appendage Closure — Should Recommendations Be Expanded? New England Journal of Medicine, Ahead of Print.
Redefining Physiology in the Cardiac Catheterization Laboratory New England Journal of Medicine, Ahead of Print.
Stenting for Post-Thrombotic Syndrome — A Step Forward New England Journal of Medicine, Ahead of Print.
Substandard Generic Drugs — Threats to Patient Safety and National Security New England Journal of Medicine, Ahead of Print.
|
|
|
| |||
|
Use of hypofractionation among underserved populations undergoing radiotherapy for cancer: Implications for policy
: To examine the use of hypofractionation among underserved populations, with a focus on implications for policy.
Tue, 28 Apr 2026 00:00:00 -0700 Temporal analysis of prostate MR-Linac data There is a strong desire to exploit daily MR-Linac (MRL) imaging for biomarker extraction and outcome prediction. Current prediction models are based on pretreatment and follow-up scans. If MRL data are to provide additional value, this would need to originate from the dynamic nature of MRL intratreatment signals. Demonstrating the existence of such dynamics and how to discover them is the purpose of this work.
Mon, 27 Apr 2026 00:00:00 -0700 One Year After a Cyberattack: Lessons Learned and Dosimetric Analysis of Contingency Radiotherapy Plans Cyberattacks on health care institutions pose significant risks to patient care, particularly in radiotherapy departments, which are heavily reliant on digital systems. This study examines the impact of a ransomware attack on our hospital and evaluates the effectiveness of the contingency measures implemented to resume radiotherapy treatments.
Mon, 27 Apr 2026 00:00:00 -0700 Outcomes of Stage IVA Cervical Cancer Treated with Radiotherapy: A Systematic Review and Meta-Analysis FIGO stage IVA cervical cancer, defined by bladder or rectal mucosal invasion without distant spread, is uncommon and understudied. This first meta-analysis exclusively on stage IVA cervical cancer aimed to synthesize survival and morbidity outcomes and identified prognostic factors influencing disease control and fistula formation.
Thu, 23 Apr 2026 00:00:00 -0700 Consolidative camrelizumab following definitive concurrent chemoradiotherapy with involved-field irradiation in locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 trial Definitive concurrent chemoradiotherapy (dCCRT) is considered the standard treatment for locally advanced unresectable esophageal squamous cell carcinoma (ESCC). However, approximately half of patients still experience local recurrence or distant metastasis. The CheckMate 577 trial demonstrated that adjuvant nivolumab significantly improves disease-free survival in patients with resected esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy. However, the role of consolidation immunotherapy in locally advanced unresectable esophageal cancer remains unclear.
Wed, 22 Apr 2026 00:00:00 -0700 FLASH Radiotherapy Mitigates Radiation-Induced Lymphopenia and Prevents Immunosuppression via Chk1-STAT3 Axis Modulation in a Preclinical Thoracic Irradiation Model Radiation-induced lymphopenia (RIL) is a frequent side effect of conventional radiation therapy (CONV RT), due to the high radiosensitivity of circulating lymphocytes. Ultra-high dose rate “FLASH” RT may preferentially spare normal tissue while maintaining tumor control. This study evaluates the impact of single-fraction and multi-fraction thoracic FLASH RT on lymphocyte preservation, apoptosis, and immunosuppressive signaling in mice.
Wed, 22 Apr 2026 00:00:00 -0700 Mechanisms, Microenvironments, and Models: Understanding Therapeutic Resistance in Glioblastoma Glioblastoma (GBM) is the most common and lethal primary malignant brain tumor in adults. Despite aggressive multimodal therapy—including maximal safe resection, radiation therapy, and temozolomide chemotherapy—median survival remains approximately 16 months, and nearly all tumors recur. Over the past two decades, numerous therapies that demonstrated promise in preclinical studies have failed to improve outcomes in randomized clinical trials, underscoring therapeutic resistance that defines this disease.
Wed, 22 Apr 2026 00:00:00 -0700 Three-dimensional radiotherapy target volume definitions for osteoarthritis – Consensus statement of the International Benign Target Volume Group (IBTVG) Low-dose radiotherapy (LDRT) is a minimally invasive treatment option for pain management in selected patients with osteoarthritis (OA). However, standardized and internationally accepted target volume definitions are still lacking.
Wed, 22 Apr 2026 00:00:00 -0700 Development and Application of a Simplified Mathematical Model for The Estimation of Tumor Dose of Non-Small Cell Lung Cancer in BNCT Lung cancer has exhibited a sustained increase in both incidence and mortality rates in recent years. This study aims to develop and apply a simplified mathematical model for estimating tumor dose in Boron Neutron Capture Therapy (BNCT) for non-small cell lung cancer (NSCLC), in order to facilitate clinical treatment planning.
Tue, 21 Apr 2026 00:00:00 -0700 Deep Learning Blood Dosimetry Predicts Severe Lymphopenia and Survival After Craniospinal Irradiation Craniospinal irradiation (CSI) is a standard treatment for pediatric brain tumors and is increasingly used for leptomeningeal metastases. While effective, CSI often causes radiation-induced severe lymphopenia (RISL), which is associated with poor outcomes across various cancer types. We developed and validated a novel platform for personalized dosimetry of circulating blood cells (CBC) and assessed its predictive value for RISL.
Tue, 21 Apr 2026 00:00:00 -0700 UNICURE-HD: A Multicentric retrospective cohort study of Single-Insertion Image-Guided HDR Brachytherapy for Locally Advanced Cervical Cancer in the context of Limited Brachytherapy access in France To assess feasibility, early outcomes, and toxicity of single-implant IGABT for LACC in a multicenter French cohort; a pragmatic strategy to address limited and uneven access to uterovaginal IGABT while preserving disease control and treatment safety.
Sat, 18 Apr 2026 00:00:00 -0700 Does Pencil Beam Scanning Proton Therapy Impart a Higher Risk of Capsular Contracture when Compared with Intensity Modulated Photon Radiotherapy in the Post-Mastectomy Reconstruction Setting? Post-mastectomy radiotherapy (PMRT) may cause adverse events in the reconstruction setting. Proton-based PMRT is increasingly utilized and has been shown to improve cardiac and pulmonary dosimetry. Data reporting the risk of capsular contracture (CC) with proton compared to photon PMRT remain scarce. We compared the CC rate of the largest cohort of pencil beam scanning (PBS) proton PMRT reconstructed patients reported to date with an intensity modulated (IMRT) photon cohort hypothesizing that the proton cohort would have a higher rate of CC.
Sat, 18 Apr 2026 00:00:00 -0700 Unraveling the Redox Mechanisms Underlying FLASH Radiotherapy: Critical Dose Thresholds and NRF2-Driven Sparing of Tissue FLASH radiotherapy (FLASH-RT) can achieve tumor control comparable to conventional dose-rate irradiation (CONV-RT) while reducing radiation damage to normal tissues. However, the physical conditions triggering the FLASH sparing effect remain unclear, and mechanisms related to oxidative stress and redox regulation are poorly understood. This study aimed to investigate the physical parameters and redox-related molecular mechanisms responsible for the FLASH effect.
Fri, 17 Apr 2026 00:00:00 -0700 Long-Term Results of a Phase II Clinical Trial of Radiation Volume and Dose De-intensification Following Transoral Robotic Surgery and Neck Dissection for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma We conducted a Phase II clinical trial reducing both dose and volume of adjuvant radiation in patients with HPV-associated OPSCC. We also examined whether postoperative circulating tumor DNA (ctDNA) was prognostic for outcomes.
Thu, 16 Apr 2026 00:00:00 -0700 Gross Tumor Volume as a Predictor of Local Control After Stereotactic Body Radiotherapy for Bone Oligometastases: A Retrospective Analysis Bone oligometastases are increasingly recognized as a clinical entity that may benefit from local therapies. Stereotactic body radiotherapy (SBRT) enables the delivery of high-dose, precise irradiation and has shown promising results in improving local control (LC) and survival. However, prognostic factors influencing LC after SBRT in patients with bone oligometastases treated with curative, metastasis-directed intent remain unclear.
Thu, 16 Apr 2026 00:00:00 -0700 Unassessed Response After Palliative Radiotherapy: A Retrospective Study of Evaluable but Not Evaluated (EBNE) Episodes Palliative radiotherapy (RT) is widely used for symptom control across diverse clinical settings. In routine practice, however, post-treatment evaluation may not be consistently documented. We examined real-world patterns of response documentation after palliative RT and identified episodes that were clinically evaluable but not formally evaluated.
Thu, 16 Apr 2026 00:00:00 -0700 |
The Myokinib monograph: operationalizing oncology’s highest-value systemic therapeutic
Volume 31, Issue 5, May 2026, oyag136 Phase II study of maintenance trifluridine/tipiracil (TAS-102) plus bevacizumab after induction chemotherapy in metastatic colorectal cancer Volume 31, Issue 5, May 2026, oyag067 Time dependent outcomes modeling in a real-world analysis of the molecular tumor board at University Cancer Center Hamburg (2016-2022) Volume 31, Issue 5, May 2026, oyag078 Gastric and rectal administration of encorafenib with targeted chemotherapy against BRAF V600E–mutant rectal cancer with bowel obstruction Volume 31, Issue 5, May 2026, oyag103 Incidental discovery of second primary lung tumors in breast cancer patients: an institutional case series Volume 31, Issue 5, May 2026, oyag083 Building HOPE: operationalizing hybrid decentralized oncology clinical trials with community providers beyond traditional healthcare system networks Volume 31, Issue 5, May 2026, oyag118 Lenvatinib combined with immune checkpoint inhibitors for unresectable, recurrent, or metastatic hepatocellular carcinoma: a real-world study Volume 31, Issue 5, May 2026, oyag097 Metabolic profile and skeletal muscle as predictors of survival in testicular germ cell tumors Volume 31, Issue 5, May 2026, oyag072 Impact of geriatric covariates on metronomic cyclophosphamide efficacy and tolerance—the CHEMETROLD study Volume 31, Issue 5, May 2026, oyag130 Cancer: a looming public health crisis in Africa—a call to accelerate equitable access to medicines Volume 31, Issue 5, May 2026, oyag089 Patients’ and healthcare providers’ views regarding dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: a qualitative study Volume 31, Issue 5, May 2026, oyag114 Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis Volume 31, Issue 5, May 2026, oyag102 Planned time burden for patients participating in phase 2 cancer trials Volume 31, Issue 5, May 2026, oyag096 Association of IDH1 mutations with survival and recurrence in resected intrahepatic cholangiocarcinoma received or not received adjuvant chemotherapy Volume 31, Issue 5, May 2026, oyag124 Landscape of T-cell engagers in solid tumors Volume 31, Issue 5, May 2026, oyag129 Identification of new prognostic molecular markers in glioblastoma: a single-center retrospective study Volume 31, Issue 5, May 2026, oyag095 Treatment strategies for small cell carcinoma of the esophagus: comparative analysis of multimodal regimens in two independent real-world cohorts Volume 31, Issue 5, May 2026, oyag115 Pivotal studies of pharmacotherapies approved by the US FDA for cancer treatment: a meta-analysis Volume 31, Issue 5, May 2026, oyag125 Feasibility and safety of short-duration aerobic training in non-hematological cancer patients hospitalized for chemotherapy treatment Volume 31, Issue 5, May 2026, oyag117 OncoEducate: a pilot study of generative AI to enhance patient–clinician communication in genitourinary cancer care Volume 31, Issue 5, May 2026, oyag135 Degrees of H2AX phosphorylation correlate with unique features of the intratumoral immune microenvironment in colorectal carcinomas Volume 31, Issue 5, May 2026, oyag116 Low opinion of generic oral anticancer drugs: an unacknowledged factor resulting in medication waste in China Volume 31, Issue 5, May 2026, oyag057 |
||
|
| |||
|
RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer
The treatment landscape for advanced pancreatic cancer is shifting. The common RAS mutation is now targetable and the race for the most effective inhibitor is heating up. Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants Dietary patterns in young patients with lung cancer suggest that many have higher dietary quality scores than average U.S. reference values, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 5039). The researchers... Monday, April 27, 2026 12:15 PM ACP Issues Controversial New Breast Cancer Screening Guidelines New guidance from the American College of Physicians (ACP) says all average-risk females between ages 50 to 74 should receive biennial screening mammography for breast cancer, and that females between the ages of 40 and 49 should discuss with their doctor their risk for breast cancer and the... Monday, April 27, 2026 11:09 AM Educational Disparities in Young-Onset Colorectal Cancer Mortality Rising colorectal cancer death rates among young adults are largely concentrated among those with lower educational attainment, according to a nationwide cross-sectional analysis published in JAMA Oncology. As a result, Jemal et al reported that the disparity in mortality between individuals with... Breast Cancer: Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxicity In a cohort study reported in JAMA Oncology, Park et al found that clonal hematopoiesis of indeterminate potential (CHIP) was associated with an increased risk of trastuzumab-related cardiotoxicity in patients with breast cancer. Long-Term Immunotherapy for Alveolar Soft Part Sarcoma Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the standard 2 years, according to results from a phase II clinical trial presented at the American... Thursday, April 23, 2026 11:14 AM AMA Data Show Nearly 50% of Surveyed Oncologists Reported Burnout in 2025 New data from the American Medical Association (AMA) show physician burnout continuing to decline nationwide, but significant differences across medical specialties underscore the need for more targeted solutions within health systems. Thursday, April 23, 2026 11:27 AM Unique Phase I NSCLC Trial Sites Decreasing in United States The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant consolidation of studies to only high trial volume sites in the country, according to the results of a... Thursday, April 23, 2026 11:00 AM Overall Survival With Addition of Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer As reported in The Lancet by Lorusso et al, the phase III ROSELLA trial has shown an improvement in overall survival with the addition of relacorilant to nab-paclitaxel in patients with platinum-resistant ovarian cancer. Relacorilant is a selective glucocorticoid receptor antagonist that acts to... Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer In a Chinese phase II trial (EC-CRT-002) reported in the Journal of Clinical Oncology, Chen et al found that the addition of the anti–PD-1 monoclonal antibody tislelizumab without maintenance cycles to induction chemotherapy and concurrent chemoradiotherapy significantly improved progression-free... Perioperative Pembrolizumab in Localized Colorectal Cancer With dMMR/MSI In a French phase II study (IMHOTEP) reported in the Journal of Clinical Oncology, de la Fouchardière et al found that perioperative pembrolizumab was active in previously untreated resectable localized colorectal cancer with mismatch repair deficiency (dMMR)/microsatellite instability (MSI). CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma Researchers at The University of Texas MD Anderson Cancer Center have identified CD40 overexpression as a potential prognostic biomarker in angioimmunoblastic T-cell lymphoma (AITL), a rare subtype of non-Hodgkin lymphoma that is difficult to diagnose and treat. The results of their study were... Bispecific Antibody Shows Deep Remission in Patients With Relapsed/Refractory Follicular Lymphoma A population of patients with highly refractory follicular lymphoma achieved long-standing responses with few significant adverse events from odronextamab monotherapy, according to findings of the ELM-2 study. The study outcomes were published by Tessoulin et al in Clinical Lymphoma, Myeloma &... Thursday, April 16, 2026 11:46 AM Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases In a Chinese phase II study (ABC) reported in the Journal of Clinical Oncology, Li et al found that the combination of the PD-L1 inhibitor adebrelimab, bevacizumab, and cisplatin or carboplatin showed high intracranial activity and progression-free survival in patients with triple-negative breast... Pretreatment MRI Prognostic Information After Radical Prostatectomy In a systematic review and meta-analysis reported in JAMA Oncology, Agrotis et al found that pretreatment MRI provided important prognostic information after radical prostatectomy in patients with prostate cancer. Early-Onset ICI-Related Myocarditis Linked to Increased Mortality Early-onset of immune checkpoint inhibitor (ICI)–related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 5212). The researchers suggested... Wednesday, April 22, 2026 11:45 AM First-Line Zongertinib in Advanced HER2-Mutant NSCLC In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced or metastatic HER2-mutant non–small cell lung cancer (NSCLC). Exposure to Wildfire Smoke May Be Linked to Increased Risk of Developing Several Types of Cancer Exposure to wildfire smoke was associated with a significantly increased risk of lung, colorectal, breast, bladder, and blood cancers, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 6252). Wednesday, April 22, 2026 10:24 AM Intralesional Nivolumab May Be Effective Against Precancerous Oral Lesions Injecting the PD-1 inhibitor nivolumab directly into precancerous oral lesions led to reduction in lesion size and allowed some patients to avoid surgery, according to research from a phase I clinical trial (ClinicalTrials.gov identifier NCT05327270) presented at the American Association for Cancer ... Wednesday, April 22, 2026 10:09 AM Metastatic NSCLC: Deep Learning Pathomics Platform May Help Predict Response to Immunotherapy A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non–small cell lung cancer (NSCLC), according to a study presented at the American Association for Cancer Research (AACR) Annual ... Tuesday, April 21, 2026 11:38 AM High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel led to a 100% measurable residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the... Tuesday, April 21, 2026 10:32 AM Methylation-Based AI Model Classifies Tumors of Unknown Origin An artificial intelligence (AI) model using DNA methylation patterns was able to classify tumors of unknown origin with high accuracy, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 3869). Tuesday, April 21, 2026 1:00 PM Initial Data Shows Safety for WEE1/PKMYT1 Inhibitor Combination in Advanced Solid Tumors Initial data from the phase I study of WEE1 inhibitor zedoresertib and PKMYT1 inhibitor lunresertib demonstrated an expected and manageable safety profile in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A gene alterations, according to findings from the MYTHIC trial... Tuesday, April 21, 2026 11:30 AM Elisrasib Demonstrates High Disease Control Rate in KRAS G12C–Mutant NSCLC Elisrasib, a next-generation KRAS G12C inhibitor, demonstrated disease control in a majority of patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), whether exposed to a prior KRAS G12C inhibitor or not, according to findings from an ongoing phase I/II clinical trial presented at the ... Monday, April 20, 2026 12:00 PM Treatment Modifications and Outcomes for Older Adults With Advanced Cancer Who Prefer Preserving QOL vs Prolonging Survival As reported in JAMA Oncology by Richardson et al, a secondary analysis of the GAP70+ trial showed that treatment modifications and outcomes did not differ between older patients with advanced cancer who prioritized quality of life (QOL) vs those who preferred prolonging survival. Zoldonrasib in Patients With KRAS G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were previously treated with chemotherapy and immunotherapy, according to preliminary findings from an... Monday, April 20, 2026 12:00 PM |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
The clinical landscape of HIF2α inhibitors in oncology
Long considered undruggable, hypoxia-inducible factor 2α (HIF2α) has now been validated as a therapeutic target in several cancers. This Review discusses the structural basis for HIF2α druggability, the clinical results to date and key challenges, including toxicities and the need for predictive biomarkers, as well as emerging targeting modalities and combination strategies that might enhance efficacy, overcome resistance and broaden indications for HIF2 inhibition. Tue, 28 Apr 2026 00:00:00 -0700 Did ATOMIC really improve on the standard of care for mismatch repair-deficient colon cancer? The ATOMIC trial has been widely celebrated as providing a positive result. However, when viewed with a lens of critical appraisal that considers issues related to overtreatment, treatment de-escalation, surrogacy, post-trial access to treatment and contributions of component, we argue that ATOMIC should not change clinical practice but rather form the basis for future trials that test de-escalation strategies. Thu, 23 Apr 2026 00:00:00 -0700 Systemic induction therapy and the expanding frontier of bladder preservation in MIBC Two recent phase II trials, INDIBLADE and SURE-02, challenge the long-standing paradigm of mandatory radical local therapy for muscle-invasive bladder cancer (MIBC). As increasingly potent systemic induction treatment strategies emerge, a key question arises: can induction therapy response guide omission of radical surgery and radiotherapy to enable preservation of an intact, functioning bladder in selected patients? Wed, 22 Apr 2026 00:00:00 -0700 Time as an unmeasured ‘dose’ in oncology: introducing time budgeting as a design principle for cancer care The burden of cancer therapy on patients’ time is often overlooked. Building on the ‘time toxicity’ literature, we introduce the concept of time budgeting, viewing patients’ time as a limited, measurable resource that can be managed through treatment selection, pathway design and trial protocols. We discuss the rationale, measurement challenges and implementation requirements to operationalize time budgeting in cancer care. Tue, 21 Apr 2026 00:00:00 -0700 OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC Wed, 15 Apr 2026 00:00:00 -0700 Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders Rare lymphoproliferative and lymphomatous disorders occurring after chimeric antigen receptor (CAR) T cell therapy are garnering increased attention but remain incompletely characterized, complicating early recognition and management. This Review describes the spectrum of post-CAR T cell therapy lymphoproliferations reported so far, highlighting recurrent pathological and molecular features as well as factors implicated in promoting clonal expansion and/or malignant transformation, which might provide a framework to improve the diagnosis and management of these disorders. Wed, 15 Apr 2026 00:00:00 -0700 A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions Myelodysplastic neoplasms (MDS) comprise a heterogeneous group of malignancies that can lead to ineffective haematopoiesis, cytopenias and, potentially, progression to acute myeloid leukaemia. In this Review, the authors describe the epidemiology of MDS, which appears to be rising, as well as advances in diagnosis, risk stratification and clinical management. Tue, 14 Apr 2026 00:00:00 -0700 Multidisciplinary management of meningiomas in the era of precision oncology Patients with meningioma, the most common type of intracranial primary tumour, have been traditionally managed with surgery and radiotherapy, although advances over the past decade have brought about promising novel treatment options. In addition, new molecularly driven classification tools can improve prognostic accuracy and guide personalized management decisions. The authors of this Review provide an integrated roadmap for meningioma care as well as a framework for ongoing and future research in this field. Mon, 13 Apr 2026 00:00:00 -0700 |
|
|
| |||
|
The association between adherence to elective nodal volume guidelines and reduced distant metastasis in esophageal and gastroesophageal junction cancer: a retrospective analysis of elective nodal irradiation
Vol 17, No 1 (February 28, 2026): Risk factors and prognostic implications of upper or middle mediastinal lymph nodes metastasis and recurrence in esophagogastric junction carcinoma Vol 17, No 1 (February 28, 2026): Identification and validation of an explainable machine learning model for early postoperative pulmonary complications after esophagectomy in patients with esophageal cancer Vol 17, No 1 (February 28, 2026): Private equity acquisitions of hospitals and the changing landscape of care for patients with gastrointestinal cancer Vol 17, No 1 (February 28, 2026): Cadonilimab plus chemotherapy vs. PD-1 inhibitor plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction cancer with PD-L1 combined positive score <5: a propensity-matched, retrospective cohort study Vol 17, No 1 (February 28, 2026): Training and validation of a nomogram for predicting synchronous distant organ metastasis in patients with very-early-onset colorectal cancer Vol 17, No 1 (February 28, 2026): Construction of taurine metabolism-related risk model and subtype identification in colorectal cancer to predict prognosis and immunological features Vol 17, No 1 (February 28, 2026): Non-surgical management of malignant bowel obstruction: strategies and outcomes in inoperable patients Vol 17, No 1 (February 28, 2026): A hybrid molecular-imaging model for high-accuracy early colorectal cancer diagnosis Vol 17, No 1 (February 28, 2026): A nine-gene nicotine-metabolism signature predicts prognosis and characterizes the immune landscape in colon adenocarcinoma Vol 17, No 1 (February 28, 2026): Overstaging of the mesorectal fascia following neoadjuvant therapy and its impact on therapeutic management: a single-center retrospective cohort study of 506 mesorectal fascia positive patients Vol 17, No 1 (February 28, 2026): ColoLDB: a machine learning-based predictive model for colorectal cancer using routine laboratory parameters Vol 17, No 1 (February 28, 2026): Colon cancer cachexia remodels gut microbiota and metabolite profiles in a murine model Vol 17, No 1 (February 28, 2026): Comparable survival outcome with anti-EGFR therapy in any treatment line in left-sided metastatic colorectal cancer Vol 17, No 1 (February 28, 2026): Association of fruit and vegetable consumption with colorectal adenoma among adults in Korea: a cross-sectional study Vol 17, No 1 (February 28, 2026): Clinicopathological characteristics and prognosis of patients with mucinous adenocarcinoma originating from the left colon, right colon, or rectum: a nationwide retrospective study in China Vol 17, No 1 (February 28, 2026): CPNE3 promotes colorectal cancer progression by regulating KIF4-mediated autophagy Vol 17, No 1 (February 28, 2026): The EZH2-NEAT1 epigenetic axis promotes cuproptosis sensitivity and modulates cancer cell migration in colorectal cancer Vol 17, No 1 (February 28, 2026): Short- and long-term outcomes after laparoscopic and open liver resection for combined hepatocellular-cholangiocarcinoma patients: a propensity score-matched study Vol 17, No 1 (February 28, 2026): Separation of liver focal nodular hyperplasia (FNH) and liver malignant tumors by a combination of T2-weighted imaging signal and three diffusion magnetic resonance metrics of diffusion-derived vessel density, slow diffusion coefficient, and apparent diffusion coefficient Vol 17, No 1 (February 28, 2026): Barcelona Clinic Liver Cancer strategy adherence in hepatocellular carcinoma and its influence on long-term outcomes Vol 17, No 1 (February 28, 2026): ΔSII-based nomogram for prognosis prediction after radical resection for hepatocellular carcinoma Vol 17, No 1 (February 28, 2026): Hedyotis diffusa Willd suppresses hepatocellular carcinoma tumor-stromal interactions by inactivating cancer-associated hepatic stellate cells Vol 17, No 1 (February 28, 2026): Clinical model for predicting overall survival outcomes in individuals with hepatocellular carcinoma: a retrospective cohort analysis Vol 17, No 1 (February 28, 2026): Global research trends and foci of ablation therapies for liver tumours: a scientometric study Vol 17, No 1 (February 28, 2026): FTSJ1-mediated IL1RN mRNA instability promotes inflammation-driven hepatocellular carcinoma Vol 17, No 1 (February 28, 2026): Development and internal validation of a predictive nomogram for early postoperative bacterial infections following liver transplantation in patients with hepatocellular carcinoma Vol 17, No 1 (February 28, 2026): Identification of mitochondrial-related subtypes and development of a prognostic model for pancreatic ductal adenocarcinoma Vol 17, No 1 (February 28, 2026): Real-world comparative effectiveness of FOLFIRINOX versus gemcitabine/nab-paclitaxel in metastatic pancreatic cancer: prognostic impact of metastatic site and burden in a Middle Eastern cohort Vol 17, No 1 (February 28, 2026): The APOBEC3 family: a narrative review of an alternative therapeutic agent for hepatitis B virus-induced hepatocellular carcinoma Vol 17, No 1 (February 28, 2026): DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer Vol 17, No 1 (February 28, 2026): Partial splenic embolization plus antitumor therapy for treating patients with hepatocellular carcinoma and splenomegaly: a case series study Vol 17, No 1 (February 28, 2026): A case report: Masson’s tumor (intravascular papillary endothelial hyperplasia) of the abdominal cavity Vol 17, No 1 (February 28, 2026): Beyond LEAP-015: the ongoing challenge of vascular endothelial growth factor inhibition in gastric cancer Vol 17, No 1 (February 28, 2026): Checkpoint inhibition in advanced biliary tract cancer: progress, limitations, and the search for biomarker-driven strategies Vol 17, No 1 (February 28, 2026): The role of chemoradiotherapy after induction in locally advanced pancreatic cancer: lessons learnt from CONKO-007 Vol 17, No 1 (February 28, 2026): In search of the best perioperative treatment for gastroesophageal cancer: is there a role for antiangiogenesis? Vol 17, No 1 (February 28, 2026): Anlotinib and penpulimab in advanced hepatocellular carcinoma: a new contender emerges Vol 17, No 1 (February 28, 2026): Regorafenib in refractory gastric cancer: modest median, meaningful milestone Vol 17, No 1 (February 28, 2026): Antiangiogenic therapy for advanced biliary tract cancers: promising or illusory? Vol 17, No 1 (February 28, 2026): Development of systemic chemotherapy starting from comparison with best supportive care: commentary on the INTEGRATE IIa phase III study Vol 17, No 1 (February 28, 2026): Bevacizumab in biliary tract cancer: a clinical catalyst in the era of chemo-immunotherapy? Vol 17, No 1 (February 28, 2026): Biology before stage in advanced gastric cancer: converting to cure in biomarker-selected patients Vol 17, No 1 (February 28, 2026): Retraction: HMGB2 upregulation promotes the progression of hepatocellular carcinoma cells through the activation of ZEB1/vimentin axis Vol 17, No 1 (February 28, 2026): |
ASO Author Reflections: Tipping Points in Rectal Cancer Organ Preservation: A Markov Model Analysis
Tue, 28 Apr 2026 00:00:00 -0700 ASO Visual Abstract: The Prognostic Rsole of Postoperative Inflammation after Minimally Invasive Resection for Colorectal Cancer Tue, 28 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Predictive Value of Routine Imaging for the Diagnosis of Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer Tue, 28 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Ki67 Gene Expression is Associated with Immune Cell Infiltration and Neoadjuvant Chemotherapy Response in ER+/HER2− Breast Cancer Tue, 28 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Eligibility for Liver Transplantation in Patients with Intrahepatic Cholangiocarcinoma Tue, 28 Apr 2026 00:00:00 -0700 ASO Author Reflections: Rethinking Lymphedema Prophylaxis After Groin Dissection for Melanoma Tue, 28 Apr 2026 00:00:00 -0700 ASO Visual Abstract: The Impact of Postoperative Complications After Colon Cancer Surgery on Locoregional Recurrence: A Population-Based Dutch Cohort Study Tue, 28 Apr 2026 00:00:00 -0700 Mapping the Evidence for Surgical Care of Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP-NETs): A Scoping Review Tue, 28 Apr 2026 00:00:00 -0700 Reply to: “Methodological Considerations on Prognostic Modeling in Esophageal Cancer—Commentary on Liu et al. (2026)” Mon, 27 Apr 2026 00:00:00 -0700 ASO Author Reflections: Redefining Parenchyma-Preserving Surgery in Advanced Hilar Cholangiocarcinoma: The Robotic Perspective Mon, 27 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Decision Modeling to Guide Management of Pancreatic IPMNs: Immediate Surgery or Initial Surveillance? Mon, 27 Apr 2026 00:00:00 -0700 ASO Visual Abstract: The Impact of Hospital Volume on Postoperative Outcomes for Esophagectomy and Gastrectomy: A Systematic Review and Meta-Analysis Mon, 27 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Robotic Caval Replacement for Leiomyosarcoma of the Inferior Vena Cava Mon, 27 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Socioeconomic Status and Survival in Sarcomas of the Breast: Nationwide Cohort Study Mon, 27 Apr 2026 00:00:00 -0700 ASO Author Reflections: Is Intervening in Metabolic Syndrome a New Direction for Improving the Prognosis After Curative-Intent Resection of Perihilar Cholangiocarcinoma? Mon, 27 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Refining the Contemporary Management of Primary Retroperitoneal Soft Tissue Sarcoma: Outcome Improvement Over Time at a Single Institution Mon, 27 Apr 2026 00:00:00 -0700 ASO Author Reflections: Digital Intelligent Technologies Assisted in Surgical Decision-Making for Minimally Invasive Treatment of Perihilar Cholangiocarcinoma Mon, 27 Apr 2026 00:00:00 -0700 ASO Author Reflections: Surgical Radicality Versus Aggressive Biology: Small Bowel and Ileocecal Involvement Predict Poorer Survival Despite Complete Cytoreduction in FIGO IIIC–IV Tubo-Ovarian and Primary Peritoneal Carcinoma Mon, 27 Apr 2026 00:00:00 -0700 ASO Author Reflections: Does Ki67 Gene Expression Capture Immune Infiltration and Predict Chemotherapy Response in ER+/HER2− Breast Cancer? Mon, 27 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Ileocecal and Small-Bowel Involvement are Independently Associated with Inferior Survival Despite Complete Cytoreduction in FIGO IIIC–IV Tubo-Ovarian and Primary Peritoneal Carcinoma Mon, 27 Apr 2026 00:00:00 -0700 The Changing Face of Gastrointestinal Cancer Mortality: Trends and Divide by Age and Geography Mon, 27 Apr 2026 00:00:00 -0700 Surgical Perspective on the Updated American College of Radiology Supplemental Screening Guidelines for Breast Density Mon, 27 Apr 2026 00:00:00 -0700 Impact of Neoadjuvant Chemotherapy on Prognosis of Patients with Mucinous Gastric Adenocarcinoma: A Propensity Score Matching Study Mon, 27 Apr 2026 00:00:00 -0700 Pulmonary Metastases After Surgical Resection of Pancreatic Ductal Adenocarcinoma: Impact on Long-Term Survival and Perspectives on Targeted Treatments Mon, 27 Apr 2026 00:00:00 -0700 Predicting Post-hepatectomy Liver Failure for Patients with Hepatocellular Carcinoma Undergoing Major Liver Resection: A Multicenter Retrospective Study Mon, 27 Apr 2026 00:00:00 -0700 Does Lymph Node Dissection During Esophagectomy Impact the Long-Term Prognosis for Complete Responders After Neoadjuvant Therapy? A Meta-analysis Mon, 27 Apr 2026 00:00:00 -0700 A Comparison of 11 Clinical Risk Scores for Prediction of Survival After Curative-Intent Resection of Colorectal Liver Metastases Mon, 27 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Surgery vs. Radiation for Stage 1A NSCLC in Nonagenarians: 20 Years of Data, Decisions, and Outcomes Fri, 24 Apr 2026 00:00:00 -0700 ASO Author Reflections: Imaging Tumor Heterogeneity to Reveal Occult Nodal Risk in Bladder Cancer Fri, 24 Apr 2026 00:00:00 -0700 Correction: Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection Fri, 24 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Association of Preoperative Inspiratory Muscle Weakness and Respiratory Sarcopenia with Postoperative Pneumonia Following Esophagectomy—A Multicenter Retrospective Cohort Study Fri, 24 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Minimizing Early-Onset Lymphedema After Groin Dissection in Metastatic Melanoma Fri, 24 Apr 2026 00:00:00 -0700 ASO Author Reflections: From Recommendation to Reality: Expert Multidisciplinary Collaboration in Intrahepatic Cholangiocarcinoma Care Fri, 24 Apr 2026 00:00:00 -0700 Maybe It Is Not in the Water: Reproducibility of Adjuvant Hepatic Artery Infusion Chemotherapy Beyond New York Fri, 24 Apr 2026 00:00:00 -0700 Preoperative Risk Assessment of Pancreatic Fistula Impact on Adjuvant Chemotherapy Delivery After Pancreatoduodenectomy Fri, 24 Apr 2026 00:00:00 -0700 Socioeconomic Status and Survival in Sarcomas of the Breast: Nationwide Cohort Study Fri, 24 Apr 2026 00:00:00 -0700 ASO Author Reflections: Redefining Surgical Margins in Multi-tumor Colorectal Liver Metastases Wed, 22 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Risk Stratification of Postoperative Recurrence After Adjuvant Nivolumab for Resected Locally Advanced Esophageal Cancer: A Real-World Study Wed, 22 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Adjuvant Radiotherapy After Pancreaticoduodenectomy for Margin-Negative, Node-Positive Pancreatic Ductal Adenocarcinoma: A Nationwide Analysis Wed, 22 Apr 2026 00:00:00 -0700 ASO Author Reflections: Shaping Renal Outcomes in CRS–HIPEC: Targeting Diuresis During Hyperthermia Wed, 22 Apr 2026 00:00:00 -0700 ASO Visual Abstract: Implications for Sentinel Lymph Node Biopsy Omission in Patients with Early Stage Node-Negative HR+/HER2− Breast Cancer Undergoing Mastectomy Wed, 22 Apr 2026 00:00:00 -0700 ASO Author Reflections: Breast Surgeons and Non-palpable Lesions—A “Magnetic” Relationship Wed, 22 Apr 2026 00:00:00 -0700 ASO Author Reflections: Neoadjuvant Oxaliplatin and Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: CT Features of Chemotherapy-Associated Liver Injury and Postoperative Complications Wed, 22 Apr 2026 00:00:00 -0700 ASO Author Reflections: From SOUND to Practice: The Economic Impact of Axillary Ultrasound-Guided Staging Wed, 22 Apr 2026 00:00:00 -0700 ASO Author Reflections: Neoadjuvant Chemotherapy Prior to CRS/HIPEC for Metachronous Colorectal Peritoneal Metastases: No Survival Gain and Increased Perioperative Risk Wed, 22 Apr 2026 00:00:00 -0700 Is Total Neoadjuvant Therapy the Solution to the Lateral Pelvic Lymph Nodes in Rectal Cancer? Retrospective Analysis From a High-Volume Tertiary Care Center Wed, 22 Apr 2026 00:00:00 -0700 The Impact of Postoperative Complications After Colon Cancer Surgery on Locoregional Recurrence: A Population-Based Dutch Cohort Study Wed, 22 Apr 2026 00:00:00 -0700 ASO Author Reflections: Does Nodal Disease Alone Warrant Adjuvant Radiotherapy after Pancreaticoduodenectomy? Tue, 21 Apr 2026 00:00:00 -0700 ASO Author Reflections: Indocyanine Green in Melanoma Sentinel Node Biopsy: Defining Its Added Value Tue, 21 Apr 2026 00:00:00 -0700 Shared Decision-Making in IPMN of the Pancreas: A Framework for Surgical Decisions Under Uncertainty Tue, 21 Apr 2026 00:00:00 -0700 |
||
|
| |||
|
Stable Supportive Footwear for Self-managing Hip Osteoarthritis Pain
Annals of Internal Medicine, Volume 179, Issue 4, Page 469-477, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19 Annals of Internal Medicine, Volume 179, Issue 4, Page 478-485, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Outcomes of Density-Targeted Supplemental Breast Magnetic Resonance Imaging Screening by Breast Cancer Risk: Long-Term Health and Economic Considerations Annals of Internal Medicine, Volume 179, Issue 4, Page 486-496, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Optimizing Cervical Cancer Screening by Age at Vaccination for Human Papillomavirus: Health and Resource Implications Annals of Internal Medicine, Volume 179, Issue 4, Page 497-505, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Hemoglobin Concentration in Early Pregnancy and Severe Neonatal Morbidity and Mortality Annals of Internal Medicine, Volume 179, Issue 4, Page 506-514, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 The Risk for Bleeding in Patients With Atrial Fibrillation From Concomitant Use of Apixaban or Rivaroxaban With Diltiazem Compared With Metoprolol Annals of Internal Medicine, Volume 179, Issue 4, Page 515-523, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians (Version 3) Annals of Internal Medicine, Volume 179, Issue 4, Page 524-534, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Care of Bereaved Persons Annals of Internal Medicine, Volume 179, Issue 4, Page 535-547, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 QUADAS-3: A Revised Tool for the Quality Assessment of Diagnostic Test Accuracy Studies Annals of Internal Medicine, Volume 179, Issue 4, Page 548-555, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 QUADAS-3 Explanation and Elaboration: Guidance for Quality Assessment of Diagnostic Test Accuracy Studies Annals of Internal Medicine, Volume 179, Issue 4, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3) Annals of Internal Medicine, Volume 179, Issue 4, Page 559-563, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 A Synopsis of the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Primary Care Management of Asthma Annals of Internal Medicine, Volume 179, Issue 4, Page 564-573, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 How Would You Manage This Patient With Frequent Migraine Headaches? Grand Rounds Discussion From Beth Israel Deaconess Medical Center Annals of Internal Medicine, Volume 179, Issue 4, Page 574-585, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Physicians Are Not Providers: The Ethical Significance of Names in Health Care: A Policy Paper From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 4, Page 556-558, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 New GRADE Evidence-to-Decision Framework for Pairwise and Multiple Comparisons (GRADE Guidance 45) Annals of Internal Medicine, Volume 179, Issue 4, Page 586-595, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 The Case Against Six-Month Limits on Buprenorphine Telehealth Prescribing Annals of Internal Medicine, Volume 179, Issue 4, Page 596-597, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Dietary Guidelines: Tilting From Treatment Toward Prevention Annals of Internal Medicine, Volume 179, Issue 4, Page 598-599, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Use of Large-Language Models for Therapy: Promise and Perils Annals of Internal Medicine, Volume 179, Issue 4, Page 600-601, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Advancing Clinical Mastery: An Essential Element of Primary Care Revitalization Annals of Internal Medicine, Volume 179, Issue 4, Page 602-603, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Supplemental Magnetic Resonance Imaging in Breast Cancer Screening: The Challenge of Using Wisely Annals of Internal Medicine, Volume 179, Issue 4, Page 604-605, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Adapting Cervical Cancer Screening in Vaccinated Populations: Individualized Versus Population-Based Approaches Annals of Internal Medicine, Volume 179, Issue 4, Page 606-607, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Small Acts of Compassion: What Current Evidence Does Not Measure Annals of Internal Medicine, Volume 179, Issue 4, Page 608-609, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 A New Approach to Reliever Therapy in Asthma: Implications of the U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline Annals of Internal Medicine, Volume 179, Issue 4, Page 610-611, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Suffering and Redemption Annals of Internal Medicine, Volume 179, Issue 4, Page 612, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Telehealth Utilization and Health Conditions Addressed Among the U.S. Medicare Population Annals of Internal Medicine, Volume 179, Issue 4, Page 614-617, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 Death at Home or Hospice Among Physicians Annals of Internal Medicine, Volume 179, Issue 4, Page 617-619, April 2026. <br/> Tue, 24 Feb 2026 08:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
|
| |||
|
Compass shares crash as ‘confounding’ survival data raise approvability questions for bispecific
While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.
Agenus cancer cocktail records 0% response rate, missing midstage goal An investigational cocktail was tied to a 0% overall response rate in patients with gastroesophageal cancer, but developers Agenus and MiNK Therapeutics aren’t giving up on the program just yet.
Merck’s early PD-1/VEGF data competitive in lung cancer, but Summit ‘looms large’ While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 readout in non-small cell lung cancer still leaves analysts with some questions moving into later-stage development.
Allogene stock sails after CAR T clears residual lymphoma in early data cut Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning.
IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy Darovasertib, in combination with crizotinib, more than doubled progression-free survival in a registrational trial, leading Truist analysts to declare a “best-in-class efficacy profile” for the PKC inhibitor.
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.”
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect gene splicing, but the biotech attributed the poor result to an outlier.
Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.
Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s immunology and inflammation pipeline.
Bioxodes to present final Phase 2a trial results confirming breakthrough potential of BIOX-101 for intracerebral hemorrhage in poster at ESOC 2026 Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson’s Disease ahead of Topline Data in 2Q26, on May 7, 2026 Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia Cantargia Announces Early Results from Trial of Nadunolimab in MDS and AML Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML Levicept to Present Data from Phase II study of LEVI-04 at OARSI 2026 World Congress on Osteoarthritis PridCor Therapeutics Secures Global Antiviral Portfolio, Establishing Leadership in Treatment of Long COVID and Infection-Associated Chronic Illnesses GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First Patient Dosed |
Compass shares crash as ‘confounding’ survival data raise approvability questions for bispecific
While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
Intellia heads to FDA after notching first late-stage win for in vivo gene editor With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for hereditary angioedema.
Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.
Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in lung cancer.
Novo’s late-stage sickle cell win piles pressure on competitors Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating “separation amongst PK class candidates,” Truist analysts said on Monday. Novo plans to seek FDA approval in the back half of 2026.
Revolution rises 40% as pancreatic cancer drug doubles survival In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. The Phase 3 results will support global regulatory filings.
IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy Darovasertib, in combination with crizotinib, more than doubled progression-free survival in a registrational trial, leading Truist analysts to declare a “best-in-class efficacy profile” for the PKC inhibitor.
Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3 Sales of Amgen’s thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025.
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of next-generation skin drugs but also shed light on how they might fare on the market.
Viridian Turns Red as Thyroid Eye Disease Data Disappoint Despite hitting its primary endpoint, Viridian’s thyroid eye disease antibody failed to ease eye bulging to the degree that analysts had been hoping for, and the biotech’s stock price fell by one-third.
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer Annovis Publishes Phase 2/3 Alzheimer’s Trial Results in Nature Portfolio Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline Zealand Pharma announces Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing Secura Bio Announces Journal of Clinical Oncology Publication of Final Results of Duvelisib PRIMO Phase 2 Trial in Relapsed/Refractory Peripheral T-cell Lymphoma Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study |
FDA alleges ‘manipulated’ data supported approval of Amgen’s autoimmune drug
The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study personnel doctored the results of the drug’s pivotal study in order to make it look effective.
Compass shares crash as ‘confounding’ survival data raise approvability questions for bispecific While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
Lilly lands third oncology deal in 3 weeks, inking up to $2.3B for Ajax Eli Lilly is picking up Ajax Therapeutics and its once-daily oral blood cancer candidate. The deal follows the pharma’s buyouts of ADC specialist CrossBridge Bio and in vivo CAR T company Kelonia Therapeutics.
Intellia heads to FDA after notching first late-stage win for in vivo gene editor With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for hereditary angioedema.
The next phase of diabetes care As technology becomes more integrated and personalized, experts say the biggest opportunity in diabetes management is reducing everyday burdens.
Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.
Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.
AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses at head and neck cancer.
Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in lung cancer.
Agenus cancer cocktail records 0% response rate, missing midstage goal An investigational cocktail was tied to a 0% overall response rate in patients with gastroesophageal cancer, but developers Agenus and MiNK Therapeutics aren’t giving up on the program just yet.
Affinia Therapeutics to Present AFTX-201 for BAG3-Associated Dilated Cardiomyopathy (DCM) and Highlight Proprietary Capsid Engineering and Manufacturing Data at the American Society of Gene & Cell Therapy 2026 Annual Meeting VectorY Therapeutics Receives U.K. MHRA Authorization and EMA Approval to Initiate Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People Living with Amyotrophic Lateral Sclerosis (ALS) PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer Kestrel Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in Patients with KRAS-driven Malignancies Annovis Publishes Phase 2/3 Alzheimer’s Trial Results in Nature Portfolio Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer Bioxodes to present final Phase 2a trial results confirming breakthrough potential of BIOX-101 for intracerebral hemorrhage in poster at ESOC 2026 Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study Zealand Pharma announces Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development |
|
|
| |||
|
FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Wed, 25 Mar 2026 00:00:02 -0700
FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).
Fri, 20 Mar 2026 00:00:02 -0700
FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myeloma On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Thu, 05 Mar 2026 00:00:02 -0800
FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Thu, 26 Feb 2026 00:00:02 -0800
FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024.
Tue, 24 Feb 2026 00:00:02 -0800
FDA approves acalabrutinib with venetoclax for chronic lymphocytic leukemia or small lymphocytic lymphoma On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Thu, 19 Feb 2026 00:00:02 -0800
FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
Tue, 10 Feb 2026 00:00:02 -0800
Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency Thu, 05 Feb 2026 00:00:02 -0800
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Tue, 27 Jan 2026 00:00:02 -0800
FDA approves amivantamab and hyaluronidase-lpuj for subcutaneous injection On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.
Wed, 17 Dec 2025 00:00:02 -0800
FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer On December 17, 2025, the Food and Drug Administration approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor-directed therapy. Patients should be selected for therapy using an FDA-approved companion diagnostic (CDx).
Wed, 17 Dec 2025 00:00:02 -0800
FDA approves fam-trastuzumab deruxtecan-nxki with pertuzumab for unresectable or metastatic HER2-positive breast cancer On December 15, 2025, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test.
Mon, 15 Dec 2025 00:00:02 -0800
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adults with deleterious or suspected deleterious BRCA2-mutated (BRCA2m) metastatic castration-sensitive prostate cancer (mCSPC), as determined by an FDA-approved test.
Fri, 12 Dec 2025 00:00:02 -0800
FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma On December 4, 2025, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company) for adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy
Thu, 04 Dec 2025 00:00:02 -0800
FDA grants traditional approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma On December 3, 2025, the Food and Drug Administration granted traditional approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. In 2023, FDA granted accelerated approval to pirtobrutinib for adults with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
Wed, 03 Dec 2025 00:00:02 -0800
FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinoma On November 25, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Tue, 25 Nov 2025 00:00:02 -0800
FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer On November 21, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin.
Fri, 21 Nov 2025 00:00:02 -0800
FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Tarlatamab-dlle received accelerated approval for this indication in 2024.
Wed, 19 Nov 2025 00:00:02 -0800
FDA grants accelerated approval to sevabertinib for non-squamous non-small cell lung cancer On November 19, 2025, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals Inc.), a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
Wed, 19 Nov 2025 00:00:02 -0800
FDA grants traditional approval to daratumumab and hyaluronidase-fihj for newly diagnosed light chain amyloidosis On November 19, 2025, the Food and Drug Administration granted traditional approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech Inc.) with bortezomib, cyclophosphamide, and dexamethasone (VCd) for newly diagnosed light chain (AL) amyloidosis. FDA granted accelerated approval for this indication in 2021.
Wed, 19 Nov 2025 00:00:02 -0800
FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas On November 19, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). FDA previously approved selumetinib capsules and granules for pediatric patients 1 year of age and older for this indication.
Wed, 19 Nov 2025 00:00:02 -0800
FDA approves epcoritamab-bysp for follicular lymphoma indications On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp (Epkinly, Genmab US, Inc.) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma (FL). The FDA also granted traditional approval to epcoritamab-bysp as monotherapy for relapsed or refractory FL after two or more lines of systemic therapy (epcoritamab-bysp was granted accelerated approval for this indication in 2024).
Tue, 18 Nov 2025 00:00:02 -0800
FDA approves new interchangeable biosimilar to Perjeta On November 13, 2025, the Food and Drug Administration approved Poherdy (pertuzumab-dpzb, Shanghai Henlius Biologics Co. Ltd.) as an interchangeable biosimilar to Perjeta (pertuzumab, Genentech Inc.). This is the first approval of a biosimilar for Perjeta.
Thu, 13 Nov 2025 00:00:02 -0800
FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation On November 13, 2025, the Food and Drug Administration approved ziftomenib (Komzifti, Kura Oncology, Inc.), a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options.
Thu, 13 Nov 2025 00:00:02 -0800
|
Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP-43 pathology.
Clin Transl Med. 2021 Feb;11(2):e336. doi: 10.1002/ctm2.336. Genç B, Gautam M, Gözütok Ö, Dervishi I, Sanchez S, Goshu GM, Koçak N, Xie E, Silverman RB, Özdinler PH Impact of high-power short-duration atrial fibrillation ablation technique on the incidence of silent cerebral embolism: a prospective randomized controlled study. BMC Med. 2023 Nov 23;21(1):461. doi: 10.1186/s12916-023-03180-3. Chen WJ, Gan CX, Cai YW, Liu YY, Xiao PL, Zou LL, Xiong QS, Qin F, Tao XX, Li R, Du HA, Liu ZZ, Yin YH, Ling ZY Molecular cloning, overexpression, and purification of a major xylanase from Aspergillus oryzae. Biosci Biotechnol Biochem. 2000 Dec;64(12):2734-8. doi: 10.1271/bbb.64.2734. Kimura T, Suzuki H, Furuhashi H, Aburatani T, Morimoto K, Karita S, Sakka K, Ohmiya K Tofersen for Amyotrophic Lateral Sclerosis: Genetic Treatment With Precision Medicine: The Future of ALS Treatment. J Clin Neuromuscul Dis. 2025 Mar 1;26(3):117-119. doi: 10.1097/CND.0000000000000517. Hamad AA Chest CT practice and protocols for COVID-19 from radiation dose management perspective. Eur Radiol. 2020 Dec;30(12):6554-6560. doi: 10.1007/s00330-020-07034-x. Epub 2020 Jul 3. Kalra MK, Homayounieh F, Arru C, Holmberg O, Vassileva J Modifiable risk factors and risk of schizophrenia and bipolar disorder across severities of genetic risk. J Affect Disord. 2026 Apr 13;407:121800. doi: 10.1016/j.jad.2026.121800. Cui Y, Sun Y, Liu S, Song J, Wang X, Li N Two Decades of Same-Sex Marriage in Sweden: A Demographic Account of Developments in Marriage, Childbearing, and Divorce. Demography. 2020 Feb;57(1):147-169. doi: 10.1007/s13524-019-00847-6. Kolk M, Andersson G Protein-templated synthesis of dinucleotide repeat DNA by an antiphage reverse transcriptase. Science. 2026 Apr 16:eaed1656. doi: 10.1126/science.aed1656. Deng P, Lee H, Armijo C, Wang H, Gao A Are Clouds a Neglected Reservoir of Pesticides? Environ Sci Technol. 2025 Oct 14;59(40):21579-21588. doi: 10.1021/acs.est.5c03787. Epub 2025 Sep 8. Bianco A, Nibert P, Wu Y, Baray JL, Brigante M, Mailhot G, Deguillaume L, Vione D, Cabanes DJE, Méjean M, Besse-Hoggan P Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy. Ophthalmol Retina. 2024 Oct;8(10):943-952. doi: 10.1016/j.oret.2024.05.003. Epub 2024 May 11. Barkmeier AJ, Herrin J, Swarna KS, Deng Y, Polley EC, Umpierrez GE, Galindo RJ, Ross JS, Mickelson MM, McCoy RG Fathers have lower salivary testosterone levels than unmarried men and married non-fathers in Beijing, China. Proc Biol Sci. 2006 Feb 7;273(1584):333-9. doi: 10.1098/rspb.2005.3311. Gray PB, Yang CF, Pope HG Jr The Size of Labia Minora and Perception of Genital Appearance: A Cross-Sectional Study. J Low Genit Tract Dis. 2017 Jul;21(3):198-203. doi: 10.1097/LGT.0000000000000308. Lykkebo AW, Drue HC, Lam JUH, Guldberg R Understanding and leveraging placebo and nocebo effects in perioperative care: a cross-sectional survey of German-speaking anesthesiologists. BMC Anesthesiol. 2026 Jan 5;26(1):70. doi: 10.1186/s12871-025-03579-w. Wessels J, Pawlik RJ, Foerster C, Erlenwein J, Benson S, Sondermann W, Elsenbruch S, Aulenkamp J Introduction: Diagnosis and management of lung cancer: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest. 2007 Sep;132(3 Suppl):20S-22S. doi: 10.1378/chest.07-1345. Alberts WM; American College of Chest Physicians An analysis of empirical estimates of sexual aggression victimization and perpetration. Violence Vict. 1999 Fall;14(3):241-60. Spitzberg BH Asundexian for Secondary Stroke Prevention. N Engl J Med. 2026 Apr 16;394(15):1467-1479. doi: 10.1056/NEJMoa2513880. Sharma M, Dong Q, Hirano T, Kasner SE, Saver JL, Masjuan J, Demchuk AM, Cordonnier C, Bereczki D, Tsivgoulis G, Veltkamp R, Staikov I, Bae HJ, Campbell BCV, Zini A, Lee IH, Kovar M, Mikulik R, Lemmens R, Ferro JM, Robinson T, Christensen H, Ozturk S, Leker RR, Turcani P, Slowik A, Amaya P, Hoo FK, De Marchis GM, Knoflach M, Sylaja PN, Putaala J, Coutinho JM, van der Worp HB, Miglane E, Matijošaitis V, Lindgren AG, Sampaio Silva G, Sandset EC, Turuspekova ST, Amarenco P, Sheth KN, Smith EE, Eikelboom JW, Joundi RA, Schulze K, Xu L, Heenan L, Colorado P, Keller L, Muehlhofer E, Neumann C, Mundl H, Shoamanesh A; OCEANIC-STROKE Investigators Diagnostic accuracy of the Gold Coast Criteria for amyotrophic lateral sclerosis: a systematic review and meta-analysis. Clin Neurophysiol. 2025 Nov;179:2111005. doi: 10.1016/j.clinph.2025.2111005. Epub 2025 Sep 15. von Quednow E, Husain N, Łajczak P, Linha Secco G, Koppanatham A Three Decades of Research on the Development of Ibogaine Treatment of Substance Use Disorders: A Scientometric Analysis. J Psychoactive Drugs. 2024 Nov-Dec;56(5):670-680. doi: 10.1080/02791072.2023.2276230. Epub 2023 Nov 6. Fernandes-Nascimento MH, Negrão AB, Viana-Ferreira K, Chaves BDR, Wang YP Perceived job insecurity and worker health in the United States. Soc Sci Med. 2009 Sep;69(5):777-85. doi: 10.1016/j.socscimed.2009.06.029. Burgard SA, Brand JE, House JS Relationship satisfaction and outcome in women who meet their partner while using oral contraception. Proc Biol Sci. 2012 Apr 7;279(1732):1430-6. doi: 10.1098/rspb.2011.1647. Epub 2011 Oct 12. Roberts SC, Klapilová K, Little AC, Burriss RP, Jones BC, DeBruine LM, Petrie M, Havlícek J |
||